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Abstract	
	
Molecular	biomarkers	are	chemical	signatures	that	all	cell	types	possess.	They	are	
used	 in	 medicine	 to	 evaluate	 both	 normal	 biological	 events	 and	 pathogenic	
processes.	A	series	of	biomarkers	associated	with	cancer	of	the	breast,	ovaries	and	
other	parts	of	the	female	reproductive	tract	and	the	monitoring	of	pregnancy	were	
measured	in	disease‐free	women.	The	biomarkers	measured	were	prostate	specific	
antigen	(PSA),	CA125,	CA15‐3,	CA72‐4,	and	pregnancy	associated	plasma	protein‐a	
(PAPP‐A).	The	patterns	of	change	during	natural	and	stimulated	ovarian	cycles	and	
early	pregnancy	were	investigated	to	determine	if	 these	biomarkers	could	reflect	
normal	events	relating	to	ovulation	and	implantation/placentation.	In	addition,	the	
study	 was	 able	 to	 investigate	 the	 possible	 erroneous	 crossing	 of	 clinical	 cut‐off	
values	 associated	with	 disease	 due	 to	 other	 biological	 processes	 rather	 than	 the	
disease	itself.	
	
A	total	of	73	blood	samples	(10	women)	taken	throughout	the	natural	menstrual	
cycle,	 64	 blood	 samples	 (11	 women)	 during	 stimulated	 ovarian	 cycles	 and	 86	
blood	samples	(14	women)	during	early	pregnancy	monitoring	were	collected	and	
all	 samples	 were	 analysed	 by	 batch	 analysis	 on	 the	 Roche	 Cobas	 e411.		
Concentrations	 of	 CA125,	 tPSA,	 CA15‐3	 and	 CA72‐4	 showed	 no	 significant	
difference	 between	 the	 natural	 and	 stimulated	 ovarian	 cycle	 groups	 (p≥0.5989).	
On	 average	 the	mean	PAPP‐A	 of	 the	 natural	 group	was	 2.41±0.58	mIU/L	 higher	
than	 the	 stimulated	group	 (t	=	4.10,	p	<	0.001).	CA125	and	CA15‐3	 results	were	
both	significantly	 influenced	by	the	stage	of	the	cycle	(p=<0.0001),	whereas	tPSA	
and	 PAPP‐A	 concentrations	 revealed	 no	 significant	 changes	 (p≥0.65).	 In	 early	
pregnancy,	 concentrations	 of	 tPSA	 (in	 the	 9/14	 (64%)	 women	 with	 detectable	
levels)	 and	PAPP‐A	 increased	 steadily	 from	4	weeks	 to	 7	weeks	 (p<0.01).	 There	
was	 a	 significant	 effect	 of	 the	 stage	 of	 gestation	 (p=0.0012)	 on	 CA125	
concentration	with	peak	levels	occurring	at	5.5	weeks	(57.98±27.45U/mL)	before	
reducing	again	by	week	7.	The	concentration	of	CA15‐3	reduced	as	the	pregnancy	
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progressed	 (p<0.0001).	 The	 CA72‐4	 concentration	 in	 pregnancy	was	 on	 average	
2.11±0.38U/ml.	
	
In	 conclusion,	 batch	 analysis	 of	 all	 samples	 from	 each	 of	 the	 participants	 was	
conducted	 to	 maximise	 the	 possibility	 that	 any	 changes	 seen	 in	 biomarker	
concentrations	 were	 due	 to	 biological	 fluctuations	 and	 not	 because	 of	 assay	
variability.	 Ovarian	 stimulation	 reduced	 serum	PAPP‐A	 levels,	whilst	 CA125	 and	
CA15‐3	were	unaffected	by	ovarian	stimulation	per	se	but	showed	cyclical	changes	
throughout	both	natural	and	stimulated	cycles.	PAPP‐A,	CA125,	 tPSA	and	CA15‐3	
all	showed	consistent	changes	in	early	pregnancy,	and	their	combined	benefits	as	
markers	 of	 different	 aspects	 of	 implantation,	 embryogenesis	 and	 placentation	
warrants	further	investigation.	Only	CA125	in	early	pregnancy	crossed	the	cut‐off	
associated	 with	 disease,	 ie	 ovarian	 cancer,	 and	 other	 gynaecological	 and	
inflammatory	 conditions.	 Care	 must	 therefore	 be	 taken	 when	 using	 CA125	
determinations	 to	 detect	 disease	 if	 the	woman	 is	 less	 than	 7	weeks	 pregnant	 as	
transient	elevations	during	this	time	appear	normal.	
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1		 Introduction	
In	1998,	 the	National	 Institutes	of	Health	Biomarkers	Definitions	Working	Group	
defined	a	biomarker	as	“a	characteristic	that	is	objectively	measured	and	evaluated	
as	 an	 indicator	 of	 normal	 biological	 processes,	 pathogenic	 processes,	 or	
pharmacologic	responses	 to	a	 therapeutic	 intervention”	(Strimbu	&	Tavel,	2010).	
However,	 many	 biomarkers	 of	 disease	 are	 often	 present	 in	 healthy	 unaffected	
people	 too,	 albeit	 at	 low	 concentrations	 and	 so	 there	 needs	 to	 be	 certainty	 that	
raised	levels	of	such	biomarkers	do	not	occur	during	normal	periods	of	increased	
cellular	 growth.	 A	 series	 of	 biomarkers	 associated	 with	 cancer	 of	 the	 breast,	
ovaries	and	other	parts	of	the	female	reproductive	tract	were	measured	in	healthy	
women	 on	 the	 basis	 that	 the	 concentration	 of	 these	 may	 be	 more	 likely	 to	 be	
affected	by	the	reproductive	status	of	the	women.	The	biomarkers	measured	in	the	
present	 study	were	prostate	 specific	 antigen	 (tPSA),	CA125,	CA15‐3,	CA72‐4	and	
pregnancy	 associated	 plasma	 protein‐a	 (PAPP‐A).	 The	 patterns	 of	 change	
throughout	 natural	 and	 stimulated	 ovarian	 cycles	 and	 in	 early	 pregnancy	 were	
investigated	to	determine	if	these	biomarkers	could	reflect	normal	events	relating	
to	 ovulation	 and	 implantation/placentation.	 In	 addition,	 the	 study	 was	 able	 to	
investigate	 the	 possible	 erroneous	 crossing	 of	 clinical	 cut‐off	 values	 associated	
with	disease	due	to	other	biological	processes	rather	than	the	disease	itself.	
		
1.1 The	Female	Reproductive	System	
1.1.1 The	Female	Reproductive	Cycle	
Throughout	a	female’s	reproductive	years	her	ovaries	and	uterus	go	through	
monthly	 cyclical	 changes	 which	 respectively	 involve	 developing	 gametes	
through	 oogenesis	 in	 the	 ovaries	 and	 preparing	 the	 uterus	 for	 possible	
implantation	 of	 an	 embryo	 (Oktem	 &	 Oktay,	 2008).	 The	 ovaries,	 the	
hypothalamus	 and	 the	 anterior	 pituitary	 are	 all	 involved	 in	 secreting	
hormones	which	control	 the	phases	of	 the	cycle.	The	 term	used	 to	describe	
the	formation	of	gametes	in	the	ovaries	is	oogenesis.	Oogenesis	begins	early	
during	 foetal	 development,	 starting	 when	 the	 primordial	 follicles	 begin	
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migrating	 from	 the	 yolk	 sac	 into	 the	 ovaries	 where	 they	 differentiate	 into	
oogonia.	 Oogonia	 are	 diploid	 with	 the	 full	 46	 chromosomes	 and	 undergo	
mitosis	to	produce	millions	of	germ	cells.	Most	of	the	germ	cells	degenerate	
through	 atresia,	 however,	 some	 will	 form	 primary	 oocytes	 which	 enter	
prophase	I	of	meiosis	and	remain	there	until	puberty	(Verlhac	&	Villeneuve,	
2010).	 The	 primary	 oocyte	 is	 surrounded	 by	 a	 flattened	 layer	 of	 follicular	
cells	 and	 is	 now	 called	 a	 primordial	 follicle.	 At	 birth,	 a	 female	 will	 have	
anywhere	 between	 200,000	 –	 2,000,000	 primary	 oocytes;	 at	 puberty	 there	
are	 approximately	 400,000	 remaining.	 In	 the	 average	 female,	 only	 400	
primary	 oocytes	mature	 and	 ovulate	 (Tortora	&	Derrickson,	 2010).	 	 At	 the	
permanent	cessation	of	the	menstrual	cycle,	a	woman	is	said	to	have	reached	
menopause,	where	approximately	1000	follicles	are	left	in	each	ovary	(Oktem	
&	Oktay,	2008).	
	
The	onset	of	menstrual	cycling	is	termed	menarche.	Young	women	who	have	
begun	menarche	will	not	usually	have	their	first	ovulation	until	around	6	or	
more	 months	 after	 commencement	 and	 the	 menstrual	 cycles	 often	 do	 not	
become	 regular	 until	 years	 later	 (Beckman	 &	 Feuston,	 2003).	 The	
proliferative	 phase	 of	 the	 uterine	 cycle,	 in	 concert	 with	 the	 ovarian	 cycle,	
involves	 building	 up	 the	 stratum	 functionalis	 of	 the	 endometrium	 of	 the	
uterus	in	the	first	two	weeks	of	the	cycle	(stimulated	by	oestrogen	from	the	
developing	 follicles	 in	 the	ovaries).	Following	 the	LH	surge,	progesterone	 is	
secreted	(at	the	expense	of	oestrogen)	as	the	follicle	becomes	luteinised	an	in	
response	the	endometrium	undergoes	secretory	changes.	If	fertilization	does	
not	occur,	progesterone	levels	(produced	by	the	remnants	of	the	follicle	that	
ovulated,	the	corpus	luteum)	drop	off	which	causes	the	stratum	functionalis	
to	slough	away	in	a	menstrual	bleed	(M.	Johnson,	2013).			
	
Gonadotrophin‐releasing	 hormone	 (GnRH)	 is	 a	 hormone	 secreted	 by	 the	
hypothalamus	 that	 stimulates	 the	 anterior	 pituitary	 to	 release	 luteinizing	
hormone	 (LH)	 and	 follicle‐stimulating	 hormone	 (FSH)	 (Richards	 &	 Pangas,	
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2010).	FSH	initiates	follicular	growth,	and	LH	stimulates	the	ovarian	follicles	
to	keep	developing.	 Just	before	mid‐cycle	 there	are	many	cumulative	GnRH	
pulses,	which	stimulate	the	concentration	of	LH	to	surge,	initiating	ovulation	
and	then	the	formation	of	the	corpus	luteum.	From	the	follicle	remnants,	the	
corpus	luteum	is	responsible	for	producing	oestrogen,	progesterone,	relaxin	
and	inhibin	(Tortora	&	Derrickson,	2010).	The	oestrogen	that	is	secreted	by	
the	 ovarian	 follicles	 is	 important	 for	 maintaining	 the	 female	 reproductive	
organs	 and	 secondary	 sex	 characteristics,	 amongst	 other	 specialised	
functions.	 Progesterone	 is	 secreted	mainly	 from	 the	 corpus	 luteum	 and	 its	
function	 is	 to	 work	 with	 the	 oestrogen	 to	 prepare	 the	 endometrium	 for	
implantation	(and	maintain	it)	as	well	as	preparing	the	mammary	glands	for	
milk	production	(Tortora	&	Derrickson,	2010).		
	
1.1.2 Phases	of	the	Female	Reproductive	Cycle	
The	typical	duration	of	 the	 female	reproductive	cycle	 is	between	24	and	36	
days,	however	most	texts	refer	to	the	cycle	as	being	28	days,	comprising	four	
phases	(Tortora	&	Derrickson,	2010).	The	menstrual	phase	is	the	first	5	days	
of	the	cycle	and	this	is	where	the	ovaries,	under	the	influence	of	FSH,	develop	
several	 of	 the	 primordial	 follicles	 into	 primary	 and	 secondary	 follicles.	
Development	of	 the	 follicles	 can	 take	 several	months	which	means	 that	 the	
follicles	that	have	just	begun	their	maturation	process	won’t	be	ovulated	until	
some	 months	 later	 (Tortora	 &	 Derrickson,	 2010).	 During	 this	 (menstrual)	
phase	 the	 oestrogen	 and	 progesterone	 levels	 decrease,	 stimulating	 the	
release	of	prostaglandins	which	causes	the	uterine	arterioles	to	constrict.	The	
constriction	of	the	arterioles	deprives	the	cells	of	the	stratum	functionalis	of	
oxygen,	killing	the	cells	so	that	they	eventually	slough	off.	The	mix	of	blood,	
mucus,	epithelial	cells	and	tissue	fluid	from	the	endometrium	flow	from	the	
uterus	through	the	cervix	and	out	of	the	vagina	to	the	exterior	as	menses	(M.	
H.	Johnson	&	Everitt,	2007).	
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Next	in	the	cycle	is	the	preovulatory	phase.	This	is	the	time	between	the	end	
of	 the	menstrual	 phase	 and	 ovulation.	 In	 a	 28	 day	 cycle	 it	 is	 recognised	 as	
lasting	 from	 day	 6	 to	 day	 13,	 however	 in	 most	 women	 this	 length	 varies	
greatly	which	is	the	main	contributor	to	the	different	cycle	lengths	between	
women	(M.	H.	 Johnson	&	Everitt,	2007).	It	 is	during	this	phase	that	some	of	
the	 secondary	 follicles	 start	 producing	 oestrogen’s	 (mainly	 17β‐oestradiol)	
and	 inhibin‐A.	 It	 is	also	around	 this	 time	 that	one	of	 the	secondary	 follicles	
(the	 dominant	 follicle)	 begins	 to	 outgrow	 the	 others	 and	 produces	most	 of	
the	oestrogens	and	inhibin‐A	(M.	H.	Johnson	&	Everitt,	2007).	The	oestrogen’s	
and	 inhibin	 down	 regulate	 the	 production	 of	 FSH	 via	 a	 negative	 feedback	
mechanism	operating	 through	 the	hypothalamus	 and	pituitary	 gland	which	
causes	all	of	the	smaller	follicles	to	stop	developing	and	undergo	atresia.	It	is	
the	dominant	follicle	that	develops	into	a	mature	Graafian	follicle	and	it	will	
continue	 to	grow	until	 it	 reaches	between	18‐22mm	in	diameter,	 forming	a	
bulging	 cyst	 on	 the	 surface	 of	 the	 ovary	 (M.	 H.	 Johnson	 &	 Everitt,	 2007).	
Paralleling	the	developing	follicles	in	the	ovaries,	the	increase	in	oestrogen	is	
helping	to	build	the	endometrial	lining	of	the	uterus	by	stimulating	the	cells	
of	 the	 stratum	 basalis	 to	 undergo	 mitosis	 and	 form	 a	 new	 stratum	
functionalis	(Tortora	&	Derrickson,	2010).		
	
Ovulation	 in	 a	 28	 day	 cycle	 happens	 on	 day	 14.	 The	 increase	 in	 oestrogen	
from	 the	 follicles	 stimulates	 the	 hypothalamus	 to	 release	 GnRH	 and	 the	
anterior	pituitary	to	secrete	LH	via	a	positive	feedback	mechanism	(Tortora	
&	Derrickson,	2010).	The	surge	of	LH	causes	the	Graafian	follicle	to	rupture,	
expelling	 the	 secondary	 oocyte	 into	 the	 pelvic	 cavity	where	 it	 is	wafted	 up	
into	the	fallopian	tube	by	the	fimbriae	(M.	H.	Johnson	&	Everitt,	2007).		
	
The	next	phase	of	the	female	reproductive	cycle	 is	 the	postovulatory	phase.	
In	 a	 28	 day	 cycle	 this	 phase	 begins	 on	 day	 15	 and	 lasts	 until	 the	 next	
menstrual	 cycle	at	day	28.	Once	 the	Graafian	 follicle	expels	 its	 contents	 the	
follicle	 collapses	 and	 a	 clot	 is	 formed	 over	 the	 rupture	 site.	 Under	 the	
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influence	of	LH,	the	granulosa	and	theca	interna	cells	combine		and	form	the	
corpus	 luteum	 (Tortora	 &	 Derrickson,	 2010).	 The	 corpus	 luteum	 begins	
secreting	oestrogens,	progesterone,	 inhibin	 and	 relaxin.	 If	 the	oocyte	 is	 not	
fertilized	the	corpus	luteum	survives	just	2	weeks	before	degenerating	into	a	
corpus	albicans	(Tortora	&	Derrickson,	2010).	The	oestrogens,	progesterone,	
inhibin	 and	 relaxin	 levels	 decrease	 and	 so	 the	 levels	 of	 LH,	 FSH	 and	GnRH	
begin	 to	 rise	 to	 start	 a	 new	 reproductive	 cycle.	 Thus,	 a	woman’s	 fertility	 is	
dependent	upon	 these	 specific	 endocrine	 events	 occurring	 in	 the	described	
succinct	order	(Richards	&	Pangas,	2010).	
	
1.1.3 Female	Hormones	and	Pregnancy	
If	 the	 ovulated	 oocyte	 is	 fertilized	 and	 the	 cell	 starts	 to	 divide,	 the	 corpus	
luteum	 survives	 past	 the	 two	 weeks	 with	 the	 aid	 of	 the	 hormone	 human	
chorionic	gonadotrophin	(hCG).	This	hormone	is	specifically	produced	by	the	
chorion	of	 the	developing	embryo	 from	8	days	post‐fertilization	 (Tortora	&	
Derrickson,	2010).	The	hCG	acts	similarly	to	LH	as	it	stimulates	the	secretory	
actions	 of	 the	 corpus	 luteum.	 The	 progesterone	 and	 oestrogen	 secreted	 by	
the	corpus	luteum	encourages	the	coiling	and	growth	of	endometrial	glands	
along	 with	 thickening	 and	 vascularisation	 of	 the	 endometrium	 (Tortora	 &	
Derrickson,	 2010).	 The	 body	 prepares	 for	 the	 implantation	 of	 the	 embryo,	
however	if	this	does	not	occur,	the	body	will	undergo	menstruation	because	
the	 progesterone	 and	 oestrogen	 levels	 decrease	 as	 the	 corpus	 luteum	
undergoes	 luteolysis	 due	 to	 absence	 of	 HCG	 which	 acts	 as	 a	 sustaining	
hormone	(M.	H.	Johnson	&	Everitt,	2007).	
	
If	 the	 embryo	 implants	 into	 the	 endometrium	 of	 the	 uterus,	 the	 corpus	
luteum	and	the	ovaries	will	continue	to	secrete	progesterone	and	oestrogens	
during	 the	 first	 three	 to	 four	months	of	pregnancy	 (M.	 Johnson,	2013).	The	
hormone	levels	in	this	period	aren’t	much	greater	than	at	ovulation;	however	
from	the	third	month	onwards	the	placenta	starts	producing	the	oestrogens	
and	 progesterone	 at	 higher	 levels	 which	 maintains	 the	 pregnancy	 (M.	
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Johnson,	2013;	O'Leary,	Boyne,	Flett,	Beilby,	&	James,	1991).	The	level	of	hCG	
peaks	 around	 week	 9	 of	 pregnancy	 and	 thereafter	 it	 declines	 until	 birth	
(Tortora	&	Derrickson,	2010).	
	
1.2 Infertility	in	Humans	
Infertility	in	humans	is	defined	as	the	inability	to	achieve	pregnancy	within	one	
year	after	having	regular,	unprotected	sexual	intercourse	(Evers,	2002).	Ogawa	
et	 al	 (2011)	 states	 that	 infertility	 affects	 approximately	 10%	 of	 all	 couples	 in	
developed	countries.	Hull	et	al.	(1985)	describe	reasons	for	infertility	along	with	
the	 approximate	 frequency	 of	 each,	which	 shows	 that	 around	15%	of	 couples	
will	 have	more	 than	 one	 cause	 of	 infertility.	Dysfunction	 in	 the	production	 or	
function	 of	 sperm	 accounts	 for	 around	 30%	 of	 infertility	 cases,	 which	 is	 the	
largest	 scoring	 of	 the	 categories.	 Ovulation	 failure	 and	 unexplained	 infertility	
both	 contribute	 25%	 of	 infertility	 cases,	 tubal	 infective	 damage	 accounts	 for	
20%,	 endometriosis	 and	 coital	 failure	 or	 infrequency	 account	 for	 5%	 each,	
cervical	mucus	defect	is	3%	and	uterine	abnormalities	<1%	(Mitwally	&	Casper,	
2003).	A	World	Health	Organization	report	stated	that	in	2003	there	were	more	
than	 186	 million	 couples	 in	 developing	 countries	 that	 were	 affected	 by	
infertility	 (World	 Health	 Organization,	 2003).	 It	 was	 highlighted	 that	most	 of	
this	 was	 attributable	 to	 the	 high	 prevalence	 of	 infectious	 diseases	 such	 as	
chlamydia	 and	 gonorrhoea	 which	 are	 linked	 with	 infertility	 (World	 Health	
Organization,	 2003).	 Assisted	 reproductive	 technology	 (ART)	 can	 help	 treat	
infertile	 couples	 unable	 to	 conceive	 naturally.	 ART	 has	 reasonably	 high	
pregnancy	 rates	 however,	 it	 is	 also	 associated	 with	 the	 risk	 of	 multiple	
pregnancies	 and	 ovarian	 hyperstimulation	 syndrome	 (Van	 Voorhis,	 2006).	
Advances	 in	 medical	 research	 have	 broadened	 our	 understanding	 of	 why	
couples	 are	 infertile.	This	has	 led	 to	 the	development	of	 a	 range	of	diagnostic	
tools	and	 thus	 treatment	options	 for	 the	 infertile	couple.	However,	Cahill	et	al	
(2002),	 states	 that	 in	approximately	25%	of	 couples,	 after	a	 full	 investigation,	
the	cause	for	their	infertility	will	not	be	found.			
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1.3 	Assisted	Reproductive	Technology	(ART)		
1.3.1	Introduction	
Assisted	 reproductive	 technology	 (ART)	 is	 the	 term	 used	 worldwide	 to	
describe	 all	 treatments	 or	 procedures	 that	 involve	 the	 in	 vitro	 handling	 of	
human	oocytes,	sperm	and	human	embryos	with	the	intention	of	achieving	a	
pregnancy	(Zegers‐Hochshild	et	al.,	2009).	The	goal	of	assisted	reproductive	
technology	 is	 to	assist	 subfertile	women	 in	becoming	pregnant	 if	 they	have	
been	unsuccessful	in	achieving	pregnancy	naturally.	The	procedures	outlined	
in	 the	 International	 Committee	 for	 Monitoring	 Assisted	 Reproductive	
Technology	 (ICMART)	 glossary	 that	 came	 under	 the	 heading	 of	 assisted	
reproductive	technologies	were;	in	vitro	fertilization	(IVF),		intracytoplasmic	
sperm	 injection	 (ICSI),	 embryo	 transfer	 (ET),	 zygote	 intrafallopian	 transfer	
(ZIFT),	 gamete	 intrafallopian	 transfer	 (GIFT),	 gamete	 and	 embryo	
cryopreservation,	 tubal	 embryo	 transfer,	 gestational	 surrogacy	 along	 with	
sperm,	oocyte	and	embryo	donation	(Zegers‐Hochshild	et	al.,	2009).		
	
Anderson	et	al.	(2008)	described	that	in	Europe,	more	than	367,000	assisted	
reproductive	 technology	 cycles	 were	 performed	 in	 more	 than	 1000	 clinics	
over	 29	 countries	 in	 the	 year	 2004.	 Annually	 Europe	 alone	 generates	 over	
85,000	 clinical	 pregnancies	 from	ART	 treatments	with	 a	 pregnancy	 rate	 of	
28%	 per	 transfer	 in	 2004	 (Andersen	 et	 al.,	 2008).	 In	 the	 United	 States	 of	
America,	 over	 100,000	 assisted	 reproductive	 technology	 cycles	 are	
performed	each	year	which	results	in	around	35,000	pregnancies	(Society	for	
Assisted	 Reproductive	 Technology	 &	 American	 Society	 for	 Reproductive	
Medicine,	2007).		
	
1.3.2 	Controlled	Ovarian	Hyperstimulation	
Controlled	 ovarian	 hyperstimulation	 is	 a	 treatment	 where	 the	 ovaries	 are	
stimulated	to	produce	multiple	mature	follicles	for	use	with	ART	treatments	
such	as	IVF	or	ICSI	(Mitwally	&	Casper,	2003).	This	form	of	controlled	ovarian	
hyperstimulation	 is	 different	 to	 ovulation	 induction	 treatment	 because	 the	
8 
 
aim	 of	 this	 treatment	 is	 to	 produce	multiple	 large	 follicles,	 compared	with	
ovulation	induction	where	multiple	follicles	are	not	the	desired	outcome.	The	
two	 most	 frequently	 used	 medications	 in	 ovarian	 stimulation	 are;	
Clomiphene	citrate	and	an	 injectable	 form	of	gonadotrophin	such	as	 follicle	
stimulating	hormone	(FSH)	(Guzick,	Carson,	&	Coutifaris,	1999).	Daily	doses	
of	 FSH	 ranging	 from	 150‐225IU	 result	 in	 a	 greater	 yield	 of	 follicles	 and	
therefore	a	greater	number	of	oocytes	for	collection	(Fauser	&	Van	Heusden,	
1997).	 The	 main	 guideline	 for	 ovarian	 stimulation	 is	 to	 maximise	 the	
beneficial	outcome	of	the	treatment;	high	oocyte	yield,	whilst	minimizing	the	
risk	 of	 over	 stimulating	 the	 ovaries	 or	 creating	 a	 multiple	 pregnancy.	 For	
these	 reasons	 close	 monitoring	 and	 adjustments	 are	 required	 based	 on	
individual	outcomes	(Fauser,	2008).		
	
Signs	of	a	diminishing	ovarian	reserve	 in	 females	 include;	an	elevated	basal	
FSH	level,	being	over	the	age	of	40	years	and	having	and	antral	follicle	count	
(AFC)	of	 fewer	 than	 five	 follicles	sized	between	2‐10mm	prior	 to	 treatment		
and	 a	 reduced	 anti‐mullerian	 hormone	 (AMH)	 (Klinkert,	 Broekmans,	
Looman,	 Habbema,	 &	 Te	 Velde,	 2005;	 Klinkert,	 Broekmans,	 Looman,	 &	 Te	
Velde,	2004).	Klinkert	et	al.	(2004)	also	explains	that	it	would	be	unusual	for	
a	 patient	with	 normal	 signs	 of	 ovarian	 reserve	 to	 have	 a	 poor	 response	 to	
gonadotrophin	stimulation.		
	
1.3.3 	IVF/ICSI	
In	vitro	 fertilization	 (IVF)	 is	 a	 procedure	 that	 involves	 extracting	an	oocyte	
from	 un‐ovulated	 follicle	 in	 the	 ovary	 and	 fertilizing	 it	 with	 	 spermatozoa,	
outside	of	the	body	in	the	laboratory	(Zegers‐Hochshild	et	al.,	2009).	IVF	can	
be	performed	on	oocytes	collected	after	the	natural	maturation	of	follicles	in	
the	 ovary	 or	 after	 the	 controlled	 ovarian	 hyperstimulation	 mentioned	
previously.	 The	 difference	 in	 outcome	 is	 the	 yield	 of	 follicles	 collected	 for	
fertilization.	 The	 biological	 age	 of	 a	 woman	 will	 affect	 her	 chances	 of	
conceiving	with	IVF	treatment.	A	study	conducted	in	the	UK	showed	that	the	
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pregnancy	rate	for	single	embryo	transfers	in	natural	IVF	cycles	was	17%	for	
women	 aged	 <30years,	 13%	 for	 women	 aged	 31‐35	 years	 and	 11%	 for	
women	aged	36‐40	years	(Healy,	Trounson,	&	Andersen,	1994).		
	
Spermatozoa	can	 fail	 to	 fertilize	an	egg,	even	when	they	are	placed	 in	close	
proximity	 to	 an	 egg	 in	 settings	 such	 as	 IVF.	 	 This	 can	 occur	 because	 of	
deficiencies	 in	 sperm	 quality	 or	 quantity	 (Gardner,	 Weissman,	 Howles,	 &	
Shoham,	2009).	Intracytoplasmic	sperm	injection	(ICSI)	is	a	procedure	which	
involves	 injecting	 a	 single	 spermatozoon	 into	 the	 cytoplasm	 of	 an	 oocyte,	
directly	 bypassing	 the	 zona	 pellucida	 and	 oolemma.	 This	 procedure	 has	
allowed	for	greater	fertilization	rates	because	men	with	deficient	numbers	of	
progressively	 motile	 sperm	 and	 men	 who	 are	 classed	 as	 azoospermic	 can	
have	 the	 sperm	 in	 the	 testis	 and	epididymis	extracted	and	 injected	directly	
into	the	egg	(Gardner	et	al.,	2009).			
	
1.4 Biomarkers		
A	biomarker	is	defined	as	“a	characteristic	that	is	measured	and	evaluated	as	an	
indicator	 of	 normal	 biologic	 processes,	 pathogenic	 processes,	 or	
pharmacological	responses	to	a	therapeutic	intervention”	(Atkinson	et	al.,	2001)	
and,	as	such,	biomarkers	can	include	a	range	of	measures	from	images	obtained	
by	X‐rays	to	molecular	biomarkers	that	can	be	measured	in	blood.	Biomarkers	
are	 used	 in	 many	 areas	 of	 medicine,	 for	 example	 oncology	 (Bhatt,	 Mathur,	
Farooque,	Verma,	&	Dwarakanath,	2010),	but	there	is	an	increased	awareness	of	
the	 potential	 benefits	 of	 biomarkers	 when	 applied	 to	 reproductive	 medicine	
(Palmer	&	Barnhart,	2013).		
	
1.4.1	Tumour	markers	
Tumour	 markers	 are	 commonly	 used	 in	 the	 detection	 and	 monitoring	 of	
cancer.	Cancer	is	an	umbrella	term	that	describes	many	different	diseases,	all	
of	which	 involve	somatic	or	germinal	cells	 that	have	alterations	 in	different	
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genes,	 allowing	 the	 cells	 to	 resist	 natural	 cell	 death	 processes,	 so	 they	
proliferate	uncontrollably	and	indefinitely	(Cho,	2007).	The	American		Cancer	
Society	projected	that	in	2012	there	would	be	1,638,910	new	cases	of	cancer	
and	 577,190	 deaths	 as	 a	 results	 of	 cancer	 in	 the	 United	 States	 (Siegel,	
Naishadham,	 &	 Jemal,	 2012).	 Using	 biomarkers	 to	 detect	 diseases	 such	 as	
cancer	plays	an	important	role	in	medicine,	and	it	is	important	to	define	the	
exact	relationship	that	the	biomarkers	have	with	the	actual	pathology.	Whilst	
tumour	 markers	 are	 often	 the	 normal	 endogenous	 products	 found	 in	 the	
plasma	and	serum	of	healthy	individuals	in	very	small	concentrations	(Trape,	
Molina,	 &	 Sant,	 2004),	 these	 molecules	 are	 produced	 by	 tumour	 cells	 in	
greater	amounts	which	can	be	an	indicator	of	cancer	presence	(Malati,	2007).	
Tumour	 markers	 can	 be	 expressed	 in	 the	 body’s	 tissues,	 present	 as	
intracellular	 substances,	 or	 they	might	 be	 released	 into	 the	 circulation	 and	
present	in	the	serum	(Bates	&	Longo,	1987;	Harnden,	1985;	Virji,	Mercer,	&	
Herberman,	 1988).	 The	 majority	 of	 tumour	 markers	 are	 proteins,	
glycoproteins,	 proteoglycans,	 carbohydrates,	 glycolipids,	 enzymes	 or	
hormones	(Sarandakou,	Protonotariou,	&	Rizos,	2007;	Trape	et	al.,	2011).		
	
When	a	cell	becomes	cancerous,	the	processes	of	differentiation	can	result	in	
the	excess	synthesis	and	release	of	molecules,	or	the	induction	of	other	cells	
to	synthesize	these	molecules	(Trape	et	al.,	2011).	The	products	that	the	cells	
produce	are	called	tumour	markers,	and	detecting	any	elevations	of	tumour	
markers	is	used	frequently	for	the	diagnosis	of	tumours,	the	prognosis	for	the	
patient,	identifying	the	stage	of	disease	and	in	monitoring	the	growth	of	the	
tumour	 (Malati,	 2007).	 The	 criteria	 for	 the	 “ideal”	 tumour	marker	 requires	
that	 it	 should	 be	 sensitive	 and	 have	 low	 false	 negatives,	 be	 highly	 specific	
with	 low	 false	 positives,	 the	 predictive	 values	 should	 be	 highly	 positive	 or	
negative	 and	 it	 should	 have	 an	 accuracy	 of	 100%	 in	 diagnosing	 and	
differentiating	between	healthy	patients	and	patients	with	 tumours	 (Malati,	
2007).	The	ideal	tumour	marker	would	show	a	positive	correlation	between	
the	tumour	marker	and	tumour	size,	predict	any	early	recurrence	of	tumour	
cells,	 have	 prognostic	 ability,	 and	 be	 able	 to	 detect	 early	 tumours	 (Bates,	
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1991).	The	ideal	tumour	marker	should	be	either	highly	specific	to	one	type	
of	 tumour	or	 a	known	universal	marker	 for	many	 tumour	 types,	 as	well	 as	
being	 straightforward	 to	 run	 as	 an	 assay,	 indicating	 any	 changes	 in	 the	
cancers	presence.	The	reality	is	that	no	one	tumour	marker	is	specific	to	any	
one	 malignancy;	 they	 are	 usually	 only	 specific	 to	 an	 organ	 or	 group	 of	
malignancies	 (Malati,	 2007).	 The	 efficacy	 of	 a	 tumour	marker	 to	 effectively	
diagnose	 disease	 relies	 on	 its	 positive	 and	 negative	 predictive	 value.	 The	
positive	predictive	value	shows	the	probability	that	the	disease	the	marker	is	
looking	for	is	actually	present	if	the	test	shows	a	positive	result.	The	converse	
applies	 for	 the	 negative	 predictive	 value,	 where	 the	 test	 result	 should	 be	
negative	 if	 there	 is	 no	 disease	 present.	 The	 sensitivity	 of	 a	 marker	 is	 if	 a	
positive	 result	 occurs	 there	 will	 positively	 be	 a	 tumour	 present	 and	 the	
specificity	 of	 the	 tumour	marker	 shows	 how	many	 healthy	 individuals	 test	
negative	for	the	marker	(Malati,	2007).	
	
Tumour	markers	can	in	some	cases	increase	in	concentration	in	patients	that	
are	healthy	and	have	no	neoplasia,	which	results	in	a	false	positive	test	result	
(Trape	 et	 al.,	 2004).	 The	 pathophysiological	 processes	 that	 are	 responsible	
for	this	increase	include	cell	necrosis	or	inflammation	which	may	lead	to	the	
release	 and	 therefore	 increase	 in	 concentrations	 of	 cell	 products	 in	 the	
serum,	or	a	dysfunction	 in	 the	organ	 that	 is	 responsible	 for	eliminating	 the	
molecule	resulting	 in	a	reduction	 in	 the	molecule’s	catabolism	(Trape	et	al.,	
2011).	Although	there	has	been	a	lot	of	research	into	cancer	biomarkers	and	
other	biomarkers	of	disease	(Palmer	&	Barnhart,	2013),	most	of	the	research	
is	 related	 to	 the	 specificity	 and	 sensitivity	 to	 the	 diseases	 the	markers	 are	
associated	with,	the	ability	to	monitor	treatment	therapies	using	biomarkers,	
and	the	strength	of	biomarkers	to	give	a	prognosis	for	disease	(Bates,	1991).	
Some	of	this	research	has	highlighted	that	these	antigens	are	also	present	in	
varying	amounts	 in	 the	 tissues,	serum	and	other	biological	 fluids	of	healthy	
individuals	 which	 could	 be	 the	 result	 of	 the	 variation	 in	 reproductive	
hormones	 releasing	 many	 growth	 factors	 and	 peptides	 that	 are	 used	 as	
tumour	 markers.	 This	 has	 led	 to	 the	 questioning	 of	 what	 the	 normal	
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fluctuations	of	 these	tumour	markers	are	 in	healthy	women	throughout	the	
natural	 menstrual	 cycle,	 stimulated	 ovarian	 cycle	 and	 early	 pregnancy	
(Palmer	 &	 Barnhart,	 2013).	 An	 understanding	 of	 the	 changes	 in	 serum	
concentrations	 of	 the	markers	 in	 healthy	 patients	 would	 allow	 for	 a	 more	
accurate	 interpretation	 of	 results	 by	 clinicians.	 The	 tumour	 markers	 that	
have	 been	 explored	 in	 this	 research	 project	 include	 the	 carbohydrate	
antigens	 CA125,	 CA15‐3,	 CA72‐4,	 and	 the	 enzyme	 prostate	 specific	 antigen	
(tPSA).		
	
1.4.1.1	Serum	CA125	
CA125	 is	 a	 tumour	 associated	 antigen	 which	 belongs	 to	 the	 family	 of	
hybridoma‐defined	 tumour	 markers	 which	 is	 used	 in	 the	 monitoring	 of	
epithelial	ovarian	carcinoma.	CA125	can	be	detected	 in	 the	serum	and	 is	
found	in	a	large	proportion	of	non‐mucinous	ovarian	tumours	that	are	of	
epithelial	 origin	 (McLemore	 et	 al.,	 2012;	 Schlageter,	 Cassinat,	 Toubert,	
Borschneck,	&	Rain,	1998;	Toki,	Kubota,	Lu,	&	Nakayama,	2000).	CA125	is	
not	present	on	the	surface	epithelium	of	normal	foetal	and	adult	ovaries;	
however	it	has	been	demonstrated	in	the	epithelium	of	the	endometrium,	
endocervix	 and	 oviduct	 (Kabawat,	 Bast,	 Welch,	 Knapp,	 &	 Colvin,	 1983).	
CA125	 has	 also	 been	 found	 in	 amniotic	 fluid	 and	 coelomic	 epithelium	
which	are	both	tissues	of	foetal	origin.	Elevated	levels	of	CA125	have	also	
been	 associated	 with	 benign	 gynaecological	 diseases	 such	 as	
endometriosis,	 cervitis,	 ovarian	 cysts,	 ovarian	 metaplasia,	 adenomyosis	
and	myomatous	uterus	 (Toki	 et	 al.,	 2000).	Based	on	 a	 study	which	used	
888	blood	donors	and	56	healthy	participants,	the	normal	value	of	CA125	
in	 the	 identification	 of	 carcinoma	 was	 set	 at	 an	 upper	 limit	 of	 35U/ml	
(Klug,	Bast,	Niloff,	Knapp,	&	Zurawski,	1984).	The	highest	levels	of	CA125	
are	 said	 to	 occur	 in	 patients	 suffering	 from	ovarian	 carcinoma,	 however	
research	has	shown	that	asymptomatic	healthy	women	can	have	elevated	
levels	 of	 CA125	without	 the	 presence	 of	 disease	 (Toki	 et	 al.,	 2000).	 One	
study	 found	 that	 in	 healthy	 women	 the	 mean	 CA125	 concentration	 is	
positively	correlated	with	age	where	12.7%	of	women	aged	40‐55	years,	
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16%	of	women	aged	56‐70	and	32.3%	of	women	aged	over	70	years	had	
serum	concentrations	of	CA125	over	the	normal	limits	(Dehaghani,	Ghiam,	
Hosseini,	Mansouri,	&	Ghaderi,	2007).	
	
Various	authors	have	suggested	that	the	circulatory	CA125	concentration	
increases	during	the	menstruation	phase	of	the	natural	cycle.	In	a	study	by	
Bon	 et	 al.	 (1999),	 the	 CA125	 concentration	 was	 measured	 in	 healthy	
women	during	spontaneous	ovulatory	cycles.	This	study	confirmed	earlier	
reports	that	there	was	a	phase	dependent	increase	in	CA125	concentration	
during	 menstruation	 in	 women	 and	 that	 there	 is	 a	 negative	 correlation	
between	 oestradiol	 and	 CA125	 levels	 in	 spontaneous	 ovulatory	 cycles	
(Haga,	 Sakamoto,	Hiroshi,	Yoshimura,	&	Akagi,	1986;	 Jager,	Meier,	Wildt,	
Sauerbrei,	 &	 Lang,	 1988;	 Pittaway	 &	 Fayez,	 1987;	 Touitou,	 Darbois,	
Bogdan,	Auzeby,	&	Keusseoglou,	1989).	CA125	was	again	examined	during	
the	menstrual	cycle	in	apparently	healthy	women	in	a	more	recent	study	
where	the	concentration	of	CA125	over	the	menstrual	cycle	was	compared	
between	 two	 different	 automated	 analysers,	 with	 the	 conclusion	 that	
CA125	 is	 highest	 during	menses	 however	 the	 changes	 are	 not	 clinically	
significant	 in	 healthy	 women	 (McLemore,	 2012).	 The	 endometrium	 has	
been	 shown	 to	 be	 responsible	 for	 the	 cyclical	 changes	 of	 CA125	 in	 the	
menstrual	cycle	however	 the	exact	mechanisms	 that	allow	 the	 release	of	
CA125	 into	 the	 circulation	 has	 not	 yet	 been	 explained	 (Kafali,	 Artunc,	&	
Erdem,	 2007;	 Ziemet,	 Muller‐Holzner,	 Marth,	 Daxenbichler,	 &	 Dapunt,	
1993).	
	
CA125	has	been	measured	throughout	ovarian	stimulation	cycles	for	ART	
treatment	showing	levels	are	significantly	higher	in	the	luteal	phase	rather	
than	 during	 the	 stimulation	 phase	 or	 at	 oocyte	 collection	 (Zweers,	 De	
Boever,	 Serreyn,	 &	 Vandekerckhove,	 1990).	 It	 has	 been	 postulated	 that	
CA125	 may	 well	 be	 a	 good	 predictor	 of	 pregnancy	 success	 for	 ART	
treatments	 because	 concentrations	 on	 the	 day	 of	 oocyte	 retrieval		
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>10IU/ml	 had	 an	 accuracy	 of	 86.6%	 for	 pregnancy,	 with	 CA125	
concentration	 being	 a	measure	 of	 endometrial	 receptivity	 and	 therefore	
predictor	of	pregnancy	success	(Tavmergen,	Sendag,	Goker,	&	Levi,	2001).	
Significant	 differences	 in	 CA125	 levels	 have	 also	 been	 shown	 between	
viable	 pregnancies	 and	 both	 anembryonic	 and	 ectopic	 pregnancies,	
however	 due	 to	 overlaps	 in	 the	 ranges	 of	 values	 for	 each	 group	 the	
findings	were	not	of	clinical	significance	(Jacobs	et	al.,	1990).	
	
Many	 authors	 have	 published	 reports	 showing	 that	 CA125	 plasma	
concentrations	 are	 increased	 during	 pregnancy	 (Aslam,	 Ong,	 Woelfer,	
Nicolaides,	&	Jurkovic,	2000;	Halila,	Stenman,	&	Seppala,	1986;	Kobayashi,	
Takashima,	ASagawa,	Mori,	&	Fujii,	1993;	Niloff,	Klug,	Schaetzl,	Reynolds,	
&	Bast,	 1984).	 Early	 reports	 from	Niloff	 et	 al.	 (1984)	 	 and	Touitou	 et	 al.	
(1989)	 showed	 that	 16%	and	12.5%	 respectively	 of	 pregnant	women	 in	
the	 first	 trimester	 had	 elevated	 levels	 of	 CA125	 and	 other	 publications	
then	 advanced	 this	 and	 concluded	 that	 20‐24%	 of	 pregnant	 women,	
regardless	of	 gestation,	had	elevated	 levels	of	CA125	 (Halila	 et	 al.,	 1986;	
Pittaway	 &	 Fayez,	 1987).	 The	 CA125	 antigen	 was	 then	 shown	 to	 be	
expressed	 during	 embryonic	 development	 where	 levels	 of	 CA125	 are	
significantly	higher	 in	the	first	and	third	trimesters	of	pregnancy	(Bon	et	
al.,	 2001;	Hardardottir	 et	 al.,	 1990).	 Other	 studies	 have	 shown	maternal	
CA125	levels	to	reach	an	average	of	85U/mL	in	the	first	trimester	and	then	
drop	 to	 the	 average	 non‐pregnant	 levels	 during	 the	 second	 and	 third	
trimester	 (Haga	 et	 al.,	 1986;	 Seki,	 Kikuchi,	 &	 Kato,	 1986).	 This	 was	
supported	 by	 a	 later	 study	 which	 showed	 peak	 CA125	 levels	 occurring	
between	weeks	 6‐7	 of	 gestation	 in	 naturally	 conceived	 pregnancies	 and	
further	 findings	where	pregnancies	achieved	via	assisted	conception	had	
levels	of	at	least	twice	those	found	in	non‐pregnant	women	(Jacobs	et	al.,	
1990).	 Research	 by	 Ocer,	 Bese,	 Saridogan,	 Aydinli,	 and	 Atasii	 (1992)	
suggested	 that	 maternal	 serum	 CA125	 >65U/ml	 in	 the	 first	 trimester	
presented	 a	 risk	 of	 spontaneous	 abortion	 of	 83.3%	 and	 that	 in	 those	
pregnancies	with	 bleeding	 lasting	 3	 or	more	 days,	 with	 elevated	 CA125	
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levels,	this	risk	rose	to	100%.	A	later	study	found	that	all	of	the	successful	
pregnancies	in	the	study	group	had	CA125	levels	<93U/ml	between	weeks	
7‐12	 gestation	 and	 those	 that	 aborted	 had	 levels	 >125U/ml	 (Azogui,	
Yaronovski,	 Zohar,	 &	 Ben‐Shlomo,	 1996).	 Furthermore,	 one	 study	 found	
that	 tubal	 pregnancies	 with	 no	 uterine	 bleeding	 had	 conversely	 much	
lower	 CA125	 concentrations	 than	 intrauterine	 pregnancies	 	 whereby	
levels	were	within	the	normal	non‐pregnant	range	of	<35U/ml	(Kobayashi	
et	al.,	1993).	
	
Some	 scientists	 hypothesize	 that	 the	 first	 trimester	 increase	 in	CA125	 is	
the	 result	 of	 decidual	 CA125	 having	 access	 to	 maternal	 circulation	 via	
tubal	reflux	because	after	the	fusion	of	the	decidua	capsularis	and	decidua	
parietalis	which	 obliterate	 the	 endometrium	 around	 10‐12	weeks,	 tubal	
closure	follows		and	then	the	maternal	CA125	levels	decrease	(Kobayashi	
et	 al.,	 1993).	 Other	 reports	 suggested	 that	 it	 is	 the	 invasion	 of	 the	
trophoblast	in	the	decidua	during	placentation	that	causes	the	increase	in	
CA125	 in	 the	 first	 trimester	and	an	 increase	 in	 the	 third	 trimester	 is	 the	
result	of	the	subsequent	deplacentation	during	which	decidual	CA125	can	
gain	access	to	the	maternal	circulation	(Kobayashi,	Sagawa,	&	Nakamura,	
1989).	 When	 indicated	 as	 a	 predictor	 of	 spontaneous	 abortion,	 authors	
suggest	 that	 the	 elevated	 CA125	 level	 is	 an	 indicator	 of	 the	 decidual	
destruction	 which	 is	 associated	 with	 pregnancy	 outcome	 (Ocer	 et	 al.,	
1992).	
	
Although	it	may	be	argued	that	CA125	has	been	investigated	extensively	in	
women,	 it	 was	 important	 that	 this	 project	 included	 CA125	 so	 that	 the	
results	 from	this	study	can	be	compared	to	previous	research	to	confirm	
that	 the	 method	 being	 used	 to	 measure	 the	 compounds	 is	 robust	 and	
reproducible	for	all	of	the	other	analytes.	This	research	aims	to	add	to	the	
current	 literature	using	the	latest	 in	automated	immunoassay	technology	
and	serial	sampling	of	individual	women.	
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1.4.1.2	Prostate	Specific	Antigen	(PSA)	
Prostate	specific	antigen	(PSA)	is	a	serine	protease	which	is	produced	by	
both	normal	and	neoplastic	epithelial	cells	of	the	prostate.	PSA	is	regulated	
by	 androgens	 and	 has	 been	 extensively	 studied	 as	 a	 biomarker	 for	
prostate	 cancer	 (Bhatt	 et	 al.,	 2010;	 Chu,	 1997;	 Luke	&	Coffery,	 1994).	 It	
was	first	discovered	in	1971,	and	then	isolated	in	1979	from	an	extract	of	
human	 prostate,	 however,	 it	 wasn’t	 until	 1980	 when	 Papsidero	 and	 his	
colleagues	 began	 measuring	 PSA	 quantitatively	 that	 its	 properties	 for	
clinical	use	as	a	biomarker	for	identifying	prostate	cancer	were	identified	
(Bhatt	et	al.,	2010;	Papsidero,	Wang,	Valenzuela,	Murphy,	&	Chu,	1980;	M.	
Wang,	Valenzuela,	Murphy,	&	Chu,	1979).	The	epithelium	of	 the	prostate	
synthesizes	PSA	and	plays	the	role	of	effectively	preventing	the	release	of	
the	protease	into	the	circulatory	system	(Malati,	2007).	PSA	can	leave	the	
prostate	and	is	often	present,	normally	in	small	amounts,	in	the	serum	of	
healthy	individuals.	The	protease	can	form	complexes	with	many	protease	
inhibitors	in	the	serum	and	seminal	fluid,	giving	rise	to	multiple	molecular	
forms	which	circulate	through	the	blood.	The	major	immunoreactive	form	
of	 PSA	 is	 the	 100KD	 complex	 PSA‐ACT,	 which	 constitutes	 up	 to	 90%	 of	
total	 PSA	 in	 the	 serum.	 There	 are	 other	 complexes,	 such	 as	 PSA‐AT	 and	
PSA‐PCI,	which	occur	at	significantly	lower	concentrations	in	the	serum	i.e.	
less	 than	 1%	 of	 PSA.	 Finally,	 PSA	 can	 form	 a	 complex	 with	 alpha‐2	
macroglobulin	 (α2	M)	which	encapsulates	 the	PSA	molecule,	masking	 the	
epitopes	 on	 the	 surface	 of	 the	 antigen	 further	 preventing	 its	
immunodetection	in	enzyme	immunoassays	(Malati,	2007).		
	
PSA	 levels	 in	 the	 serum	 are	 often	 elevated	 in	men	with	 prostate	 cancer	
which	 has	made	 it	 the	most	 clinically	 significant	 tumour	marker	 for	 the	
disease	 (Papsidero	 et	 al.,	 1980).	 This	 led	 to	 the	 American	 Urological	
Association	 (AUA)	 and	 the	 Food	 and	 Drug	 Administration	 (FDA)	 in	 the	
United	 States,	 originally	 promoting	 recommendations	 that	 all	 men	 over	
the	 age	 of	 50	who	 have	 no	 family	 history	 of	 prostate	 cancer,	 and	 those	
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with	a	family	history	who	are	over	the	age	of	40,	have	annual	digital	rectal	
examinations	for	prostate	abnormalities	as	well	as	serum	PSA	level	checks	
(Malati,	2007).	However,	prostate	cancer	can	be	present	in	the	body	even	
when	the	serum	level	for	PSA	is	not	elevated	(Thompson	et	al.,	2004).		Due	
to	this,	there	have	been	many	calls	to	stop	using	PSA	as	a	routine	screening	
test	in	men	and	now	it	is	no	longer	used	in	the	USA	(Friedrich,	2011).		
	
Prostate‐specific	 antigen	 has	 certainly	 been	 incorrectly	 named	 since	
advances	in	the	sensitivity	of	technology	have	shown	PSA	to	be	expressed	
in	females	(Aksoy,	Akcay,	Umudum,	Yildirim,	&	Memisogullari,	2002;	Giai	
et	al.,	1995).	PSA	was	found	to	be	expressed	by	normal,	hyperplastic	and	
neoplastic	female	breast	tissue	where	it	 is	present	in	30%‐40%	of	breast	
tumours	 in	 females	 (H.	 Yu,	 Diamandis,	 &	 Sutherland,	 1994;	 H.	 Yu	 et	 al.,	
1995).	 The	 PSA	 concentration	 does	 not	 correlate	 with	 the	 reproductive	
hormones	 LH,	 FSH	 and	 oestradiol,	 however,	 it	 is	 said	 to	 follow	 the	
progesterone	 concentration	 peak	 (N.	 Zarghami,	 L.	 Grass,	 E.	 Sauter,	 &	 E.	
Diamandis,	 1997).	 Steroid	 hormone	 receptor‐positive	 breast	 carcinoma	
cell	 line	T‐47D	was	used	in	a	tissue	culture	system	which	reproduces	the	
process	 of	 PSA	 production	 by	 breast	 cells	 to	 show	 that	 only	 upon	
stimulation	by	steroid	hormones	does	the	cell	line	produce	PSA	in	a	dose‐
dependent	 manner	 (N.	 Zarghami	 et	 al.,	 1997).	 According	 to	 one	 study	
investigating	 women	 over	 the	 age	 of	 50	 years,	 PSA	 levels	 are	 not	
significantly	 different	 between	 healthy	 women	 and	 those	 with	 breast	
cancer	(Giai	et	al.,	1995).	
	
Further	 studies	 have	 shown	 that	 PSA	 is	 produced	 in	 a	 cyclical	 manner	
during	the	natural	menstrual	cycle	where	the	peak	concentration	is	during	
the	mid	 to	 late	 follicular	 phase	 and	 lowest	 during	 the	mid	 to	 late	 luteal	
phase	 of	 the	 cycle	 (N.	 Zarghami	 et	 al.,	 1997).	 These	 findings	 have	 been	
confirmed	by	a	later	study	which	showed	PSA	concentrations	in	the	saliva	
of	 women	 were	 increased	 in	 the	 follicular	 phase	 and	 around	 mid‐cycle	
18 
 
compared	 to	 the	 luteal	 and	 early	 follicular	 phases	 (Aksoy,	 Akcay,	 et	 al.,	
2002).	 Prostate	 specific	 antigen	 concentrations	 are	 very	 low	 in	 female	
serum	and	 it	 is	 not	 known	why	 some	women	have	measurable	 levels	 of	
PSA	and	others	do	not.	Zarghami	et	al.	(1997)	suggest	that	it	is	because	of	
an	 inability	 of	 PSA	 to	 diffuse	 out	 of	 the	 breast	 tissue	 into	 the	 blood	
circulation.		
	
Prostate	specific	antigen	was	identified	in	amniotic	fluid	during	pregnancy	
where	 the	 concentration	 increased	 from	 11	 weeks	 until	 21	 weeks	 of	
gestation	before	 it	decreased	 	until	birth	 (H.	Yu	et	al.,	1995).	 	This	study	
also	found	that	PSA	is	in	greater	concentrations	in	the	serum	of	pregnant	
women	compared	to	non‐pregnant	women	(H.	Yu	et	al.,	1995).	The	same	
group	also	detected	PSA	 in	 the	breast	milk	of	 lactating	women,	 although	
concentrations	 were	 variable	 between	 women	 and	 its	 biological	 role	 in	
milk	 is	 still	 unknown	 (H.	 Yu	 &	 Diamandis,	 1995).	 As	 such,	 this	 led	 the	
authors	to	suggest	that	as	well	as	serving	as	a	growth	factor	regulator	 in	
cancer,	 PSA	 may	 play	 a	 role	 in	 normal	 foetal	 development	 throughout	
pregnancy.	 There	 are	 conflicting	 opinions	 about	 PSA	 and	 its	 role	 in	 pre‐
natal	 screening	 for	 Down	 Syndrome.	 One	 study	 conducted	 in	 1998	
concluded	 that	 the	concentration	of	PSA	 in	Down	Syndrome	pregnancies	
was	significantly	higher	than	in	normal	pregnancies	(Lambert‐Messerlian,	
Canick,	 Melegos,	 &	 Diamandis,	 1998).	 However,	 another	 study	 from	 the	
same	year	could	not	confirm	that	there	was	any	variation	in	maternal	PSA	
concentrations	with	gestational	age	nor	could	they	confirm	that	maternal	
PSA	 levels	 were	 increased	 in	 pregnancies	 affected	 by	 Down	 Syndrome	
(Spencer	 &	 Carpenter,	 1998).	 Another	 study	 found	 PSA	 in	 the	
endometrium	of	the	uterus	and	that	it	may	play	a	role	in	uterine	regulation	
(Mannello	 et	 al.,	 1996).	 Although	 the	 physiological	 role	 and	 biological	
significance	 of	 PSA	 is	 still	 not	 completely	 understood	 it	 has	 been	
hypothesised	 as	 a	 growth	 factor	 regulator	 which	 is	 produced	 by	 cells	
exhibiting	steroid	hormone	receptors	(E.	Diamandis	&	H.	Yu,	1995).		
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1.4.1.3	Serum	CA15‐3	
CA15‐3	is	a	mucin‐like	glycoprotein	encoded	by	the	gene	MUC1	which	was	
first	identified	by	two	monoclonal	antibodies	115D8	and	DF3	(Kamal	et	al.,	
2011;	 Schlageter	 et	 al.,	 1998).	 	Mucins	 provide	 a	 protective	 layer	 on	 the	
surface	of	epithelial	cells	by	providing	lubrication,	preventing	dehydration	
and	protecting	against	proteolysis	due	to	 its	high	degree	of	glycosylation	
(Al‐Azemi,	 Refaat,	 Aplin,	 &	 Ledger,	 2009).	 MUC1	 is	 heterogeneously	
expressed	on	 the	 surface	of	 epithelial	 cells,	 including	 those	 in	 the	breast	
and	 upper	 reproductive	 tract	 and	 is	 thought	 to	 prevent	 embryo	
implantation	 (Al‐Azemi	 et	 al.,	 2009).	 Meseguer	 et	 al.	 (2001),	 suggesting	
that	the	human	blastocyst	can	produce	certain	factors	that	remove	MUC1	
from	a	 site	 to	 facilitate	 implantation	 in	 the	 endometrium.	 	 Expression	of	
MUC1	has	been	shown	to	be	progesterone	dependent	and	is	up	regulated	
in	 endometrial	 epithelial	 cells	 in	 the	 luteal	 phase	 of	 the	menstrual	 cycle	
(Aplin,	Hey,	&	Graham,	1998;	Hey,	Graham,	Seif,	&	Aplin,	1994).		
	
Serum	levels	of	CA15‐3	are	considered	normal	if	they	are	under	the	upper	
limit	of	25	U/ml	(Bhatt	et	al.,	2010).	Elevated	levels	of	CA15‐3	in	women	
with	 breast	 cancer	 were	 identified	 as	 being	 involved	 in	 the	 cancer’s	
metastasis	(Duffy,	Shering,	Sherry,	McDermott,	&	O'Higgins,	2000).	Of	the	
many	different	tumour	markers	that	have	been	examined	in	breast	cancer,	
CA15‐3	is	used	most	extensively	as	its	expression	in	most	breast	cancers	is	
greatly	 increased	 (Clinton	et	al.,	 2003;	O'Brien,	Gough,	 Skehill,	Grimes,	&	
Given,	 1994).	 In	women	with	 breast	 cancer,	 where	 the	 disease	 status	 is	
operable,	 around	 11%	 of	 cases	 have	 elevated	 levels	 of	 CA15‐3,	 and	 in	
those	with	metastatic	breast	cancer,	60%	have	elevated	 levels	 (Park,	Oh,	
Kim,	&	Kim,	2008).	Post‐operative	prognosis	for	patients	with	high	CA15‐3	
concentrations	 is	 much	 worse	 than	 for	 those	 with	 low	 concentrations,	
although	 it	 has	 been	 found	 that	 patients	with	 high	 serum	CA15‐3	 levels	
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have	 a	 good	 response	 to	more	 aggressive	 treatments	 (Park	 et	 al.,	 2008;	
Shering,	Sherry,	McDermott,	Higgins,	&	Duffy,	1998).			
	
However,	 the	 sensitivity	 of	 CA15‐3	 for	 marking	 breast	 cancer	 has	 been	
reported	as	being	low	due	to	high	levels	in	benign	breast	tissue	diseases,	
ovarian,	 lung,	 pancreatic,	 stomach,	 uterine	 and	 colorectal	 cancers	 and	
hepatic	dysfunction	(Duffy	et	al.,	2000;	Nalini,	Delphine,	Silvia,	Makhija,	&	
Uthappa,	2005;	Sakaguchi,	2004).	Elevated	concentrations	of	CA15‐3	have	
been	found	in	patient	serum	where	there	is	an	absence	of	neoplasia	(Trape	
et	al.,	2011).	In	a	study	conducted	on	post‐menopausal	women	who	were	
all	asymptomatic	and	healthy,	5.9%	had	serum	concentrations	of	CA15‐3	
higher	than	the	cut‐off	25	U/ml	(Dehaghani	et	al.,	2007).	CA15‐3	has	been	
found	 in	 the	 serum	 of	 patients	 with	 cobalamin	 deficiency	 and	
macrocytosis	 in	 concentrations	 that	 are	 ten	 times	 the	 upper	 reference	
limit	 for	healthy	people	 (Symeonidis	 et	 al.,	 2004).	Amoura	 (2005)	 found	
that	 22%	 of	 patients	 suffering	 different	 inflammatory	 myopathies	 had	
serum	concentrations	of	CA15‐3	over	the	upper	reference	limit,	suggesting	
that	there	may	be	other	factors	influencing	serum	CA15‐3	concentrations.		
	
Research	 into	 other	 tumour	 markers	 such	 as	 CA125,	 as	 mentioned	
previously,	 has	 shown	 that	 the	 fluctuations	 in	 some	 tumour	 marker	
concentrations	 are	 phase	 dependent	 in	 the	 menstrual	 cycle	 of	 healthy	
women.	 Bon	 et	 al.	 (1999)	 described	 the	 differences	 in	 CA15‐3	
concentrations	 in	different	phases	of	 the	 spontaneous	ovulatory	 cycle	 as	
being	 not	 of	 statistical	 significance.	 However,	 another	 report	 found	
conflicting	 results	 whereby	 they	 showed	 significant	 phase	 dependent	
differences	 in	 CA15‐3	 concentrations	 throughout	 the	 menstrual	 cycle	
(Erbagci,	Yilmaz,	&	Kutlar,	1999).	Dehaghani	et	 al.	 (2007)	showed	 that	a	
group	 of	 women	 with	 a	 history	 of	 using	 the	 oral	 contraceptive	 pill	 for	
greater	than	one	year	had	a	significantly	larger	number	of	subjects	within	
the	normal	range	for	CA15‐3,	with	only	1	out	of	the	76	women	above	the	
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normal	 upper	 limit	 compared	 to	 11	 out	 of	 127	 women	 in	 the	 group	 of	
women	who	did	not	use	oral	contraceptives.	
	
Different	 studies	 have	 found	 that	 CA15‐3	 concentrations	 in	 pregnancy	
vary	 between	 slightly	 elevated,	 moderately	 elevated	 and	 significantly	
elevated	(Cheli	et	al.,	1999;	Panidis,	Vlassis,	Matalliotakis,	Skiadopoulos,	&	
Kalogeropoulos,	 1988).	 When	 comparing	 levels	 from	 each	 trimester,	
although	 levels	were	shown	 to	 increase	with	gestation	 they	do	not	cross	
clinical	thresholds	(Bon	et	al.,	2001;	Correale	et	al.,	1993;	Schlageter	et	al.,	
1998;	Touitou	et	al.,	1989).	The	rise	in	maternal	serum	concentrations	of	
CA15‐3	during	the	latter	stages	of	pregnancy	has	been	suggested	to	be	due	
to	 the	 proliferation	 of	 the	 breast	 epithelium	during	 this	 phase	 or	 that	 it	
might	be	an	artefact	of	the	immunoassay	as	it	was	developed	against	milk‐
fat	 globule	 membranes	 (Bon	 et	 al.,	 2001;	 Hilkens	 et	 al.,	 1984).	 Other	
studies	 have	 found	 that	 concentrations	 of	 CA15‐3	 do	 not	 change	
significantly	with	pregnancy	and	that	it	can	still	be	used	as	a	biomarker	for	
breast	 cancer	 if	 gestational	 related	 reference	 ranges	 are	 put	 in	 place	
(Botsis	et	al.,	1999;	Touitou	et	al.,	1989).		
	
1.4.1.4	Serum	CA72‐4	
CA72‐4	is	a	tumour	associated	antigen	that	is	defined	through	its	reactivity	
with	the	two	murine	monoclonal	antibodies	CC‐49	and	B72‐3	(Hareyama,	
Sakuragi,	Makinoda,	&	Fujimoto,	 1996).	CA72‐4	was	once	described	as	 a	
useful	 tumour	 marker	 for	 all	 epithelial	 derived	 tumours	 and	 gastric	
carcinomas	 (Ohuchi,	 Takahashi,	 &	Matoba,	 1989).	 This	 research	 showed	
that	 the	 sensitivity	 of	 CA72‐4	 for	 gastric	 carcinoma	 was	 38%,	 which	 is	
greater	than	the	tumour	markers	CA19‐9	which	is	33%,	CEA	at	31%	and	
CA125	at	21%	(Ohuchi	 et	 al.,	 1989;	Villena,	Lopez	Encuentra,	&	Ecvhave	
Sustaet,	1996).	CA72‐4	was	postulated	as	a	 complimentary	biomarker	 to	
CA125	 in	 the	 screening	 of	 ovarian	 cancer,	 where	 one	 study	 found	 that	
when	 combining	 the	 biomarkers	 the	 sensitivity	 for	 detecting	 early	 stage	
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disease	increased	from	45%	to	70%	(Skates	et	al.,	2004).	With	advances	in	
technology	 in	 recent	years,	 immunoassays	are	now	much	more	 sensitive	
so	 any	 evidence	 from	 this	 time	 is	 somewhat	 limited.	 These	 antibodies	
recognise	 the	 tumour	 associated	 glycoprotein	 (TAG‐72)	 in	 the	 serum	 of	
patients	 with	 various	 adenocarcinomas	 as	 well	 as	 in	 foetal	 epithelium	
(Ohuchi	et	al.,	1989;	Villena	et	al.,	1996).	
	
1.4.2	Reproductive	Markers	
1.4.2.1	Reproductive	Hormones	
Reproductive	 hormones	 such	 as	 oestradiol,	 progesterone,	 luteinizing	
hormone	 (LH)	 and	 human	 chorionic	 gonadotrophin	 (hCG)	 are	measured	
and	evaluated	as	indicators	of	normal	biological	processes	and	events	that	
occur	 throughout	 the	natural	menstrual	 cycle	and	 in	pregnancy	 (O'Leary	
et	al.,	1991;	Sherman	&	Korenman,	1975).	These	hormones	are	also	useful	
tools	in	assisted	reproductive	medicine	as	they	are	measured	throughout	
exaggerated	 biological	 processes	 like	 those	 during	 hyperstimulated	
ovarian	 cycles	 for	 IVF/ICSI	 to	 monitor	 follicle	 growth	 and	 endometrial	
development	(Wikland	&	Hillensjo,	2004).		
	
During	the	menstrual	cycle,	oestradiol	is	produced	in	increasing	amounts	
by	 the	 granulosa	 cells	 of	 the	 developing	 follicle	 and	when	 the	 follicle	 is	
mature	 it	 will	 trigger	 luteinizing	 hormone	 to	 surge	 to	 induce	 ovulation.	
The	follicular	phase	is	variable	between	women	as	shown	by	Cole,	Ladner,	
and	 Byrn	 (2009)	 where	 the	 timing	 of	 the	 LH	 peak	 was	 between	 10‐20	
days.	The	phase	after	ovulation	is	called	the	 luteal	phase	which	has	been	
shown	 to	 be	 consistent	 in	 length	 between	women	 (McIntosh,	Matthews,	
Crocker,	Broom,	&	Cox,	1980),	where	oestradiol	and	progesterone	prepare	
the	 endometrium	 for	 implantation	 and	 serum	 concentrations	 of	
progesterone	will	start	to	increase	from	ovulation	and	are	maintained	by	
the	 corpus	 luteum	 if	 pregnancy	 is	 achieved.	 Human	 chorionic	
gonadotrophin	 (hCG)	 is	 a	 hormone	 produced	 by	 the	 chorion	 of	 the	
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developing	embryo	from	around	8	days	post	fertilisation	where	maternal	
serum	concentrations	double	every	2‐3	days.	These	reproductive	markers	
were	 measured	 in	 all	 women	 throughout	 this	 study	 to	 ensure	 accurate	
timing	of	biological	events	throughout	all	three	groups	of	cycles.	
	
1.4.2.2	Pregnancy‐associated	plasma	protein‐A	(PAPP‐A)	
Pregnancy‐associated	plasma	protein‐A	(PAPP‐A)	was	identified	as	one	of	
four	 proteins	 found	 in	 the	 serum	 of	 pregnant	 women	 in	 1974	 and	 was	
later	documented	as	being	produced	by	the	syncytiotrophoblastic	cells	of	
the	 placenta	 where	 it	 is	 released	 in	 increasing	 amounts	 into	 maternal	
circulation	with	increasing	gestation	(Folkersen,	Grudzinskas,	Hindersson,	
Teisner,	&	Westergaard,	1981;	Lin,	Galbert,	Kiefer,	Spellacy,	&	Gall,	1974).	
The	concentration	of	maternally	circulating	PAPP‐A	is	reduced	in	the	first	
trimester	 of	 pregnancies	 that	 are	 affected	 by	 trisomy	 18,	 trisomy	 21,	
blighted	ova	and	 is	also	associated	with	with	 IUGR	(intra‐uterine	growth	
retardation)	causing	low	birth	weight,	premature	birth	and	pre‐eclampsia	
(Brizot	 et	 al.,	 1996;	 D'Antonio	 et	 al.,	 2013;	 Dane,	 Dane,	 Batmaz,	 Ates,	 &	
Dansuk,	2013;	Poon,	Maiz,	Valencia,	Plasencia,	&	Nicolaides,	2009;	Smith	
et	 al.,	 2002;	 NJ	 Wald,	 Watt,	 &	 Hackshaw,	 1999;	 Yovich,	 Willcox,	
Grudzinskas,	 Chapman,	 &	 Bolton,	 1986).	 Early	 reports	 suggested	 that	
reduced	PAPP‐A	concentrations	in	maternal	serum	are	due	to	altered	post‐
translational	events	which	affect	protein	transport	across	the	placenta	or	
its	 secretion,	 rendering	 PAPP‐A	 screening	 tests	 useful	 as	 a	 marker	 of	
placental	function	(Brizot	et	al.,	1996).	First	trimester	combined	screening	
tests	 measure	 PAPP‐A	 and	 free	 β‐hCG	 at	 9‐12	 weeks	 as	 well	 as	 nuchal	
translucency	 by	 ultrasound	 at	 11‐13	 weeks.	 This	 is	 combined	 with	 the	
gestational	age,	maternal	age	and	weight	to	give	an	estimate	of	the	risk	of	
the	foetus	having	trisomy	18	or	21	(bAmor	et	al.,	2009).		
	
Children	 born	 as	 a	 result	 of	 ART	 in	 2008	 accounted	 for	 3.3%	 of	 all	 live	
births	 in	Australia	 (Y.	A.	Wang,	Chambers,	&	Sullivan,	2010).	There	have	
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been	 comparisons	 made	 between	 serum	 biomarker	 concentrations	 for	
second	 trimester	 screening	 in	 naturally	 conceived	 pregnancies	 and	 IVF	
conceived	pregnancies.	 In	some	studies	PAPP‐A	 levels	were	shown	 to	be	
reduced	in	pregnancies	conceived	via	ART	(Anckaert,	Schiettecatte,	Sleurs,	
Devroey,	&	Smitz,	2008;	bAmor	et	al.,	2009;	Bersinger	et	al.,	2004;	Hui	et	
al.,	2005;	Liao,	Heath,	Kametas,	Spencer,	&	Nicolaides,	2001;	Matilainen	et	
al.,	 2011;	Maymon	 &	 Shulman,	 2002a,	 2004;	 Orlandi	 et	 al.,	 2002;	 Tul	 &	
Novak‐Antolic,	 2006),	 however	 in	 others	 there	 was	 no	 significant	
difference	(Bellver	et	al.,	2005;	Ghisoni	et	al.,	2003;	Lambert‐Messerlian	et	
al.,	2006;	Niemimaa	et	al.,	2001;	Wojdemann	et	al.,	2001).	Tul	and	Novak‐
Antolic	 (2006)	 found	 a	 correlation	 between	 the	 number	 of	 oocytes	
retrieved	 with	 PAPP‐A	 concentrations,	 whereby	 higher	 oocyte	 numbers	
results	 in	 a	 lower	 PAPP‐A,	 leading	 to	 the	 suggestion	 that	 the	 difference	
may	 be	 due	 to	 the	 multiple	 corpora	 lutea	 present.	 bAmor	 et	 al.	 (2009)	
found	 that	PAPP‐A	 levels	were	 reduced	 in	both	 fresh	and	 frozen‐thawed	
embryo	 transfers	 when	 compared	 to	 naturally	 conceived	 pregnancies,	
however,	 fresh	 transfers	did	have	 significantly	 lower	PAPP‐A	 levels	 than	
frozen‐thawed	 transfers.	 They	 also	 showed	 that	 there	was	no	 significant	
difference	 in	PAPP‐A	 levels	between	 IVF,	 ICSI	 and	GIFT	subtypes	of	ART	
pregnancies.	
	
Increases	in	false‐positive	rate	(FPR)	in	prenatal	screening	tests	for	Down	
syndrome	have	been	reported	for	pregnancies	conceived	through	assisted	
reproduction	 (bAmor	 et	 al.,	 2009;	 Barkai	 et	 al.,	 1996;	 Frishman	 et	 al.,	
1997;	Lambert‐Messerlian	et	al.,	2006;	Orlandi	et	al.,	2002;	Ribbert	et	al.,	
1996;	 N.	 Wald,	 White,	 Morris,	 Huttly,	 &	 Canick,	 1999).	 Having	 a	 lower	
PAPP‐A	 level	 at	 first	 trimester	 screening	and	 therefore	 receiving	a	 false‐
positive	 result	 (FPR)	 might	 subsequently	 lead	 to	 unnecessary	
amniocentesis	 procedures	 exposing	 these	 pregnancies	 to	 undue	 risk.	
However,	after	adjustment	for	maternal	age	many	other	studies	conclude	
that	the	FPR	is	not	increased	in	ART	pregnancies	(Bellver	et	al.,	2005;	Liao	
et	 al.,	 2001;	 Matilainen	 et	 al.,	 2011;	 Maymon	 &	 Shulman,	 2002b;	
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Wojdemann	et	al.,	2001).	Contradictory	results	such	as	these	suggest	that	
there	may	be	many	confounding	factors	on	these	prenatal	screening	tests	
such	 as	 exogenous	 hormone	 treatment	 regimens	 which	 have	 been	
suggested	 as	 the	 reason	 for	 lower	 PAPP‐A	 levels	 in	 these	 pregnancies	
(bAmor	et	al.,	2009;	Bersinger	et	al.,	2004;	Hui	et	al.,	2005;	Tul	&	Novak‐
Antolic,	2006).	
	
1.5 Aims	of	the	Study	
The	 study	 combined	 the	measurement	 of	 several	 biomarkers	 using	 the	 latest	
generation	of	immunoassays,	with	the	serial	monitoring	of	individual	women	in	
three	different	 reproductive	 situations	namely	natural	 and	 stimulated	ovarian	
cycles	as	well	as	early	pregnancy.	 	A	better	understanding	of	 the	behaviour	of	
such	 biomarkers	 in	 women	 may	 help	 us	 monitor	 reproductive	 events	 more	
clearly,	 as	well	 as	 assist	 in	 the	 clinical	 interpretation	of	 these	markers	 should	
they	be	 elevated	 above	 clinical	 threshold	 for	 disease.	The	 aims	 of	 the	 present	
study	were	therefore:	
1. To	 use	 the	 current	 generation	 of	 immunoassays	 to	 measure	 selected	
serum	 biomarkers	 (CA125,	 Prostate	 specific	 antigen	 [PSA],	 CA15‐3,	
CA72‐4	and	PAPP‐A)	in	women	of	reproductive	age,	and	to	describe	the	
assay	performance	characteristics	at	these	levels.	
2. Measure	 these	 compounds	 in	 disease‐free	 women	 during	 the	 natural	
menstrual	cycle,	stimulated	ovarian	cycle	and	early	pregnancy.	
3. Identify	 changes	 in	 these	 biomarkers	 that	 may	 give	 additional	
information	about	ovarian	function,	implantation	and	placentation.	
4. Determine	 if	 these	 markers	 exceed	 the	 clinical	 thresholds	 associated	
with	disease,	and	identify	any	possible	need	to	revise	reference	ranges	
in	the	different	reproductive	phases.	
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2 Materials	and	Methods	 	
2.1 Participants	
2.1.1	Ethics	Approval	
Ethics	 approval	 was	 granted	 by	 the	 Joondalup	 Health	 Campus	 Research	
Ethics	 Committee	 [JHCREC,	 Project	 1216]	 and	 the	 Edith	 Cowan	 University	
Human	Research	Ethics	Committee	[ECUHREC,	Project	7281],	see	appendices	
1	and	2.	
	
2.1.2	Selection	of	Participants	
Participants	 recruited	 for	 this	 research	 project	 were	 women	 attending	
Fertility	 North	 for	 fertility	 treatment.	 None	 of	 the	 women	 had	 evidence	 of	
cancer	or	endometriosis.	On	each	given	day	that	the	clinic	was	open,	women	
on	 current	 treatment	 plans	 came	 to	 the	 clinic	 in	 the	 morning	 between	
7:00am	and	8:30am	to	have	their	blood	taken	as	part	of	 their	management.	
To	identify	which	patients	were	due	for	blood	collection	on	each	day,	we	used	
an	 electronic	 diary	 (Genie;	 Genie	 Solution	 Pty	 Ltd,	 Indooroopilly,	
Queensland)	 which	 lists	 all	 women	 attending	 the	 clinic	 on	 that	 day.	 The	
program	 permits	 all	 of	 the	 patient’s	medical	 information	 and	 history	 to	 be	
retrieved	at	any	given	time.	On	each	day	during	the	recruitment	period,	 the	
list	of	patients	was	screened	to	determine	which	women	were	attending	for	
their	 first	 blood	 sample	 of	 their	 cycle	 that	 day	 and	what	 type	 of	 treatment	
they	were	starting.	If	they	were	day	2	of	a	natural	cycle	or	a	fresh	IVF	or	ICSI	
cycle,	 these	women	were	approached	 that	morning	and	recruited	using	 the	
information	letter	and	consent	 forms	approved	by	the	two	governing	ethics	
committees.	If	there	were	any	women	starting	a	pregnancy	monitoring	cycle	
of	 blood	 sampling	 then	 these	 women	 were	 also	 approached	 in	 the	 same	
manner.		
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2.1.3	Study	Cycles	
2.1.3.1	Natural	Menstrual	Cycle	
Participants	 in	 this	 study	 group	 included	 women	 who	 were	 attending	
Fertility	 North	 for	 a	 tracking	 cycle	 which	 takes	 place	 in	 the	 initial	
investigation	 prior	 to	 commencing	 fertility	 treatment.	 These	women	 are	
on	no	medications	 that	affect	 the	natural	 reproductive	 cycle	e.g.	 the	oral	
contraceptive	 pill	 or	 hormone	 replacement	 therapy.	Blood	was	 taken	on	
day	2‐3	of	the	natural	cycle,	where	the	first	day	of	menses	is	called	day	1.	
Oestradiol,	progesterone,	LH	and	FSH	are	measured	from	this	first	sample.	
The	 next	 blood	 sample	 was	 taken	 5‐7	 days	 later	 when	 the	 oestradiol,	
progesterone	 and	 luteinizing	 hormone	 concentrations	 were	 measured.	
These	 three	 hormones	 were	 measured	 until	 ovulation.	 Ovulation	 was	
defined	 as	 being	 when	 there	 was	 a	 serum	 LH	 surge	 and	 a	 rise	 in	
progesterone	 concentration	 from	 a	 baseline	 level.	 This	 was	 then	
confirmed	by	ovarian	ultrasound	when	the	 leading	 follicle	could	be	seen.	
Seven	 days	 after	 ovulation	 the	 woman’s	 oestradiol	 and	 progesterone	
concentration	were	measured	as	an	indication	of	luteal	function,	and	then	
at	 fourteen	 days	 after	 ovulation	 a	 pregnancy	 test	 was	 performed	 by	
measuring	 oestradiol	 and	 progesterone	 as	 well	 as	 human	 chorionic	
gonadotrophin	(hCG).	
	
2.1.3.2	Stimulated	Ovarian	Cycle	
Participants	 in	 this	 study	 group	 included	women	 starting	 an	 IVF	 or	 ICSI	
cycle	 at	Fertility	North.	These	women	had	 their	blood	 taken	on	day	2	of	
their	 cycle	where	 the	 oestradiol,	 progesterone,	 luteinizing	 hormone	 and	
follicle	 stimulating	hormone	 concentrations	were	measured.	The	women	
embarked	 on	 a	 stimulatory	 regimen	 using	 a	 protocol	 including	 either	 a	
GnRH	 agonist	 in	 a	 short	 down	 regulation	 (flare)	 cycle	 (Frydman	 et	 al,	
1988;	Garcia	et	al,	1990;	Acharya	et	al,	1992),	long	down	regulation	cycle	
(Porter	 et	 al,	 1984;	 Shaw	 et	 al,	 1985)	 or	 a	 GnRH	 antagonist	 in	 an	
antagonist	 cycle	 (Diedrich	 et	 al,	 1994).	 After	 6	 days	 of	 receiving	 FSH	
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injections	 the	 women	 returned	 for	 another	 blood	 test	 to	 measure	 their	
oestradiol	and	follicle	stimulating	hormone	levels	to	gauge	their	response	
to	stimulation.	The	oestradiol	 levels	were	measured	approximately	every	
2	 days	 during	 stimulation	 to	 further	 monitor	 the	 ovarian	 response	 and	
identify	 whether	 an	 increased	 dose	 of	 FSH	 was	 required	 due	 to	 a	 low	
response,	 or	 if	 the	 woman	 was	 at	 risk	 of	 ovarian	 hyperstimulation	
syndrome	 (OHSS)	 because	 of	 an	 inordinately	 high	 response.	 Seven	 days	
after	 the	 patient	 was	 triggered	 to	 ovulate,	 another	 blood	 test	 was	
performed	to	measure	the	oestradiol	and	progesterone	levels.	At	fourteen	
days	after	ovulation,	the	patient	had	a	pregnancy	test	indicating	oestradiol,	
progesterone	and	human	chorionic	 gonadotrophin	 (hCG)	 concentrations.	
If	the	woman	was	pregnant	she	had	a	blood	test	every	two	or	three	days	to	
measure	 her	 progesterone	 and	 hCG	 levels	 until	 she	 had	 a	 visible	 foetal	
heart	beat	identified	by	ultrasound	around	seven	weeks	gestation.		
	 	
2.1.3.3	Early	Pregnancy		
Participants	 in	 this	 group	 included	 women	who	 had	 undergone	 fertility	
treatment	at	Fertility	North	and	had	become	pregnant	as	a	 result	of	 this	
treatment.	At	 fourteen	days	after	ovulation	women	had	a	pregnancy	 test	
which	 measured	 their	 oestradiol,	 progesterone	 and	 human	 chorionic	
gonadotrophin	 (hCG)	 levels.	 A	 hCG	 concentration	 of	 >25	 IU/mL	 is	
regarded	 as	 a	 positive	 pregnancy	 test	 and	 the	 hCG	 concentration	 should	
approximately	double	every	 two	to	 three	days.	Therefore,	blood	samples	
were	taken	every	two	to	three	days	during	an	early	pregnancy	monitoring	
cycle,	 until	 the	 woman	 had	 an	 ultrasound	 scan	 at	 around	 6‐7	 weeks	 of	
gestation.	Women	 in	 this	 study	 group	 take	 one	 200mg	Progesterone	BD	
pessary	(Orion,	Balcatta	WA)	which	helps	to	support	the	pregnancy.	
	
2.2 	Serum	Collection	&	Storage	
All	blood	samples	were	collected	by	Fertility	North	phlebotomists	on	site.	Blood	
was	 collected	 using	 syringes	 and	 transferred	 into	 5ml	 Vacutainer	 SST™	 tubes	
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(Becton	Dickinson,	UK),	 labelled	and	bagged,	before	delivery	 to	 the	 laboratory	
with	 a	 request	 form.	 Receipt	 of	 the	 sample	 by	 the	 laboratory	 was	 then	
confirmed	 by	 adding	 the	 patient	 and	 requested	 tests	 to	 the	 “blood”	 screen	 in	
Genie	for	that	day,	and	selecting	the	patient	as	per	the	daily	blood	samples.	The	
sample	 was	 then	 allocated	 a	 laboratory	 number,	 with	 copies	 of	 the	 bar	 code	
being	placed	on	 the	blood	 tube	and	on	 the	pathology	referral	 form.	The	blood	
was	allowed	to	clot	at	room	temperature	and	then	centrifuged	at	4000rpm	for	4	
minutes.	 The	 sample	 was	 then	 analysed	 for	 the	 requested	 reproductive	
hormones	 according	 to	 the	 patient’s	 treatment	 and	 then	 stored	 at	 ‐80˚C	 for	
retrospective	analysis	of	tumour	markers	at	a	later	date.	Once	each	patient	had	
finished	 having	 blood	 samples	 collected,	 all	 of	 the	 blood	 samples	 from	 that	
completed	 treatment	 cycle	 were	 thawed	 at	 room	 temperature	 and	 then	
analysed	 for	biomarker	 concentrations	 in	 one	batch	 analysis	 on	 the	 same	day	
that	 they	were	 thawed.	Once	 the	 sample	was	analysed,	 any	excess	 serum	was	
replaced	into	the	‐80˚C	freezer	for	storage.	The	research	detailed	in	this	thesis	
was	carried	out	between	February	2012	and	December	2013.	
	
2.3 Determination	of	Serum	Hormone	Concentration	
The	 Siemens	 Centaur	 CP	 Automated	 Analyser	 (Siemens,	 Bayswater,	 Victoria	
3053,	 Australia)	 was	 used	 to	 measure	 oestradiol,	 luteinising	 hormone	 (LH),	
progesterone	and	human	chorionic	gonadotrophin	(hCG).	
	
2.3.1	Basic	Assay	Procedure	
The	 automated	 analyser	 was	 run	 daily	 according	 to	 the	 manufacturer’s	
instructions	 and	 the	 standard	 operating	 procedure	 of	 Fertility	 North	
[Appendix	3].	All	 reagents	were	 stored	and	used	 as	per	 the	manufacturer’s	
instructions	as	shown	in	Table	1	and	Appendix	5	[Chapter	3].	To	reconstitute	
calibrators	 and	 control	material,	 the	 pipette	 pump	with	 a	 glass	 volumetric	
pipette	was	used	to	deliver	deionised	water	(Ibis	Technology,	Mt	Hawthorn).	
A	record	of	the	sample,	the	date	of	reconstitution	and	the	date	of	expiry	were	
written	on	the	side	of	the	reagent	bottles.		
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2.3.2	Internal	and	External	Quality	Control	
Internal	 quality	 control	 for	 each	 assay	 was	 performed	 using	 the	 BioRad	
Immunoassay	 Plus	 1,	 2,	 3	 (Bio‐Rad	 Laboratories,	 Irvine,	 CA)	 in	 each	 run.	
Ligands	were	reconstituted	to	5	mls	and	7	x	600µl	lots	aliquotted	for	the	next	
7	 days.	 All	 results	were	 stored	 by	 the	 Advia	 Centaur	 CP	 automatically	 and	
transferred	 to	 a	 computer	 on	 a	monthly	 basis	 into	QC	 reporter	 2.	 A	 repeat	
patient	 sample	 from	 the	 previous	 day	 was	 also	 run	 and	 results	 recorded	
daily.	All	of	 the	reproductive	hormone	assays	were	also	assessed	using	 two	
external	quality	assurance	 schemes	named	RCPA	Endocrine	 scheme	(RCPA,	
New	 South	 Wales)	 and	 EQASRM	 (EQASRM,	 Western	 Australia).	 These	
schemes	were	 used	 as	 a	means	 to	 compare	 the	 results	 generated	 from	 the	
method	being	used	to	the	results	of	other	laboratories	in	the	country	that	are	
also	using	the	same	method.	
	
2.4 Determination	of	Serum	Biomarker	Concentration	
The	Roche	Cobas	e411	Automated	Analyser	(Roche	Diagnostics,	Germany)	was	
used	to	measure	the	biomarkers;	PAPP‐A,	CA125,	CA15‐3,	CA72‐4	and	total	PSA	
(tPSA).	This	was	done	as	a	batch	analysis	to	minimise	variability	attributable	to	
the	reagent	stability.		
	
2.4.1		Basic	Assay	Procedure	
The	 automated	 analyser	 was	 run	 daily	 according	 to	 the	 manufacturer’s	
instructions,	 and	 the	 standard	 operating	 procedure	 of	 Fertility	 North	
[Appendix	4].	All	 reagents	were	 stored	and	used	 as	per	 the	manufacturer’s	
instructions	as	shown	in	Table	2	and	Appendix	6	[Chapter	3].	The	lyophilized	
calibrators	 and	 control	 material	 were	 reconstituted	 with	 deionised	 water	
(Ibis	 Technology,	 Mt	 Hawthorn)	 as	 shown	 in	 Appendix	 7.	 A	 record	 of	 the	
sample	the	date	of	reconstitution	and	the	date	of	expiry	was	written	on	the	
side	of	the	reagent	bottles.	The	reagent	kits	were	stored	in	the	biochemistry	
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refrigerator	at	2‐8˚C	until	use.	After	opening,	they	were	stable	for	12	weeks	at	
2‐8˚C	or	3‐8	weeks	on‐board	the	analyser.	When	 in	use	reagent	packs	were	
removed	 from	 the	 fridge	 and	 placed	 on	 the	 reagent	 rotor	 with	 the	 lids	
unclipped	after	 coming	 to	 room	 temperature.	The	 temperature	of	 the	 rotor	
was	 controlled	 at	 20˚C.	 Reagents	 were	 left	 to	 warm	 to	 this	 temperature	
before	use.	The	rotor	lid	was	replaced	and	locked	once	all	reagent	packs	were	
loaded.	After	use,	the	lids	on	the	reagent	bottles	were	snapped	closed	and	the	
reagent	is	placed	back	into	the	refrigerator	for	storage	until	its	next	use.	
	
2.4.2		Calibrations	
The	 reagent	 kits	 were	 calibrated	 within	 24hours	 after	 the	 initial	 opening.	
Thereafter,	renewed	calibrations	were	required	every	7	days	per	reagent	kit	
until	all	tests	were	used.	The	Roche	CalSet	specific	to	each	of	the	assays	were	
used	 to	 calibrate	 the	 reagent	 kits.	 The	 calibrators	 come	 in	 liquid	 and	
lyophilized	form	and	were	all	stored	at	2‐8˚C	on	receipt	and	these	were	stable	
until	the	stated	expiry	date.	The	lyophilized	calibrators	were	reconstituted	as	
per	 the	 manufacturer’s	 instructions	 and	 once	 reconstituted	 the	 calibrators	
were	 stored	 at	 2‐8˚C	 where	 they	 were	 stable	 for	 6	 weeks.	 Aliquots	 of	
reconstituted	calibrator	were	frozen	at	‐20˚C	where	they	were	stable	for	12	
weeks	 until	 thawed	 for	 use.	 The	 calibrators	 were	 left	 to	 warm	 to	 room	
temperature	before	use	and	the	reconstituted	aliquots	were	used	only	once.	
	
2.4.3	Internal	and	External	Quality	Control	
Internal	quality	 control	was	assessed	using	 the	Elecsys	PreciControl	Tumor	
Marker	(Roche	Diagnostics,	Germany)	with	two	levels,	the	BioRad	Lyphochek	
Tumor	 Marker	 Plus	 Control	 (Bio‐Rad	 Laboratories,	 Irvine,	 CA)	 and  the 
Elecsys	PreciControl	Maternal	Care	(Roche	Diagnostics,	Germany)	with	three	
levels,	which	were	run	each	day	that	an	assay	was	performed	and	after	every	
calibration.	 	The	CA125	assay	was	enrolled	 in	an	external	quality	assurance	
scheme	(RCPA,	Endocrine	scheme)	under	Fertility	North	however	there	were	
no	 external	 quality	 assurance	 schemes	 available	 for	 the	 other	 biomarker	
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assays.	Reconstitution	details	and	stability	of	the	quality	control	material	are	
given	in	Appendix	7.	The	assay’s	performance	characteristics	are	described	in	
Table	1	[Chapter	3].	
 
2.5 Statistical	Analysis	
Measurement	 of	 quality	 control	 samples	 was	 expressed	 as	 the	 mean	 and	
standard	deviation,	to	allow	the	calculation	of	coefficients	of	variation.	However,	
the	results	of	clinical	samples	are	expressed	as	means	and	standard	error	of	the	
mean	 (sem)	 as	 an	 estimate	 of	 how	 close	 to	 the	 population	mean	 the	 sample	
mean	is	likely	to	be.	
	
For	the	ovarian	cycle	analyses,	a	linear	mixed	effects	model	was	used	to	test	the	
mean	 differences	 in	marker	 concentration	 between	women	 in	 stimulated	 and	
natural	 cycles	 across	 the	 cycle	 phases.	 For	 each	model,	 the	 response	 variable	
(CA125,	 tPSA,	CA153	and	PAPP‐A)	was	 log	 transformed	before	analysis	as	 the	
data	 appeared	 non‐normal	 and	 thus	 the	 error	 distribution	 might	 affect	 the	
calculation	 of	 standard	 errors	 and	 the	 p‐values	 required	 for	 null	 hypothesis	
testing.	Group	(IVF	and	‘natural’)	and	Phase	were	included	as	fixed	effect	factors	
and	‘Subject’	and	‘Time’		were	modelled	as	random	effects	(as	in	some	subjects	
there	 were	 multiple	 time	 points	 measured	 within	 phases).	 The	 interaction	
between	Group	and	Phase	was	also	modelled.	The	analysis	was	done	using	the	R	
version	3.0.0	computing	software	(R	Core	Team,	2013).	Models	were	built	using	
the	‘nlme’	(Pinheiro,	Bates,	DebRoy,	Sarkar,	&	R	Development	Core	Team,	2012).	
Small	sample	size	and	gaps	in	IVF	sampling	due	to	the	nature	of	IVF	need	to	be	
taken	into	account	in	cautiously	interpreting	this	data.		
	
For	 the	early	pregnancy	analyses	the	response	variable	(tPSA,	CA125,	CA15‐3,	
PAPP‐A	 and	 hCG)	 was	 log	 transformed	 before	 analysis	 as	 the	 data	 appeared	
non‐normal	 and	 thus	 the	 error	 distribution	 might	 affect	 the	 calculation	 of	
standard	errors	and	the	p‐values	required	for	null	hypothesis	testing.	Gestation	
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was	 included	as	 fixed	effect	 factors	and	 ‘Subject’	 and	 ‘Time’	were	modelled	as	
random	effects	(as	in	some	subjects	there	were	multiple	time	points	measured	
within	 the	 phase).	 The	 interaction	 between	 Group	 and	 Gestation	 was	 also	
modelled.	The	analysis	was	done	using	the	R	version	3.0.0	computing	software	
(R	Core	Team,	2013).	Models	were	built	using	the	‘nlme’	(Pinheiro	et	al.,	2012)	
mixed	models	package	and	graphics	were	produced	using	the	‘ggplot2’	package	
(Wickham,	2009).	
	
2.6 Day	and	Phase	of	Cycle	
The	menstrual	cycle,	as	described	earlier,	is	considerably	variable	in	length	from	
day	one	of	the	cycle	to	ovulation.	In	order	to	normalise	the	follicular	phase	for	
statistical	analysis	a	formula	was	applied	to	calculate	an	adjusted	day	(Hadlow	
et	al.,	2013).	
Adjusted	day	=	Actual	day	x	(14/Actual	day	of	ovulation)	
The	menstrual	cycle	was	further	divided	into	seven	phases	using	the	day	of	the	
cycle	(Hehenkamp	et	al.,	2006)	relative	to	ovulation	as;	
(1) Early	Follicular	(EF)	‐	10	days	or	more	before	ovulation	
(2) Mid	Follicular	(MF)	‐	6	to	9	days	before	ovulation	
(3) Late	Follicular	(LF)	‐	2	to	5	days	before	ovulation	
(4) Periovulatory	(PO)	‐	1	day	before	ovulation	
(5) Ovulation	(O)	‐	the	day	of	ovulation	
(6) Mid‐Luteal	(ML)	–	5	to	8	days	after	ovulation	
(7) Late	Luteal	(LL)	–	9	to	14	days	after	ovulation	
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3.0 Results	
3.1	Performance	characteristics	of	Roche	automated	immunoassays	
used	to	measure	CA125,	tPSA,	CA15‐3,	CA72‐4	and	PAPP‐A.	
Results	obtained	with	the	Biorad	Lyphochek	Tumor	Marker	Plus	trilevel	quality	
control,	 Roche	 Elecsys	 PreciControl	 Tumor	Marker	QC	 bi‐level	 quality	 control	
material	 and	 Roche	 Elecsys	 PreciControl	 Maternal	 Care	 QC	 tri‐level	 quality	
control	material	 are	 shown	 in	 Table’s	 1	 and	 2	 .	 The	 reproducibility	 of	 results	
from	each	assay	was	described	by	calculating	 the	coefficient	of	variation	(CV).	
Good	reproducibility	was	shown	in	the	measurement	of	CA125	(CV	<6.2%)	and	
CA15‐3	 (CV	 <7.5%).	 PAPP‐A	 and	 tPSA	 were	 more	 variable	 (CV	 <11.4%	 and	
<13.4%	 respectively)	 and	CA72‐4	was	more	 so	 (CV	<20.4%).	 	 The	BioRad	QC	
material	 appeared	 to	 give	 greater	 reproducibility	 compared	 to	 the	 Roche	 QC	
such	that	all	of	the	CV’s	were	lower	for	the	BioRad	QC	for	6	of	the	8	QCs.		
	
The	variability	associated	with	the	measurement	of	serum	is	shown	in	Table	3	
where	 pooled	 serum	 from	women	 recruited	 in	 the	 study	was	 analysed	 daily.	
Similar	patterns	were	seen	with	the	CA125	(CV	<4.7%)	and	CA15‐3	(CV	<6.5%).	
However,	the	low	concentrations	of	CA72‐4,	PAPP‐A	and	tPSA	resulted	in	higher	
variability	with	CVs	of	<24.1%,	<27.0%	and	<38.5%	respectively.	Estimates	of	
within‐run	 variability	 seen	 with	 clinical	 samples	 are	 shown	 in	 Table	 4,	 with	
PAPP‐A,	 CA125,	 CA15‐3	 and	CA72‐4	 all	 being	 <5.0%.	 tPSA	was	more	 variable	
with	a	CV	of	12.94%.		
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Table	 1.	 Between‐run	 variability	 assessed	 using	 commercially	
available	 quality	 control	 material	 (CA125,	 CA15‐3,	 CA72‐4	 and	
tPSA).	
 
Table	 2.	 Between‐run	 variability	 assessed	 using	 commercially	
available	quality	control	material	(PAPP‐A).	
	
	
	
Marker	 Level	
Biorad	Lyphochek	Tumor	
Marker	Plus	
Elecsys	PreciControl	
Tumor	Marker	
µ	±	sd	 CV	(%)	 µ	±	sd	 CV	(%)	
CA125	
U/ml	
(n=43)	
Low	
Medium	
High	
28.45	±	1.46	
70.67	±	4.02	
194.66	±	6.74	
5.12	
5.69	
3.46	
28.52	±	1.75	
‐	
87.30	±	4.40	
6.13	
‐	
5.04 
CA15‐3	
U/ml	
(n=42)	
Low	
Medium	
High	
22.25	±	1.41	
57.12	±	3.97	
111.48	±	7.55	
6.32	
6.95	
6.77 
18.52	±	1.39	
‐	
84.58	±	5.85	
7.49	
‐	
6.92	
CA72‐4	
U/ml	
(n=33)	
Low	
Medium	
High	
4.54	±	0.87	
11.98	±	1.72	
44.84	±	3.25	
19.15	
14.33	
7.26	
4.94	±	1.01	
‐	
44.75	±	5.19	
20.44	
‐	
11.61 
tPSA	
ng/ml	
(n=45)	
Low	
Medium	
High	
0.072	±	0.01	
3.30	±	0.29	
15.55	±	1.45	
13.39	
8.84	
9.31	
‐	
3.90	±	0.35	
39.33	±	3.63	
‐	
9.04	
9.23 
Marker	 Level	 Elecsys	PreciControl	Maternal	Care	µ	±	sd	 CV	(%)	
PAPP‐A	
mIU/L	
(n=38)	
Level	1	
Level	2	
Level	3	
5535.63	±	629.03	
2761.58	±	256.88	
271.42	±	20.65	
11.36	
9.30	
7.61	
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Table	3.	Pooled	human	serum	showing	between‐run	variability.	
	
	
Table	4.	Pooled	human	serum	showing	within‐run	variability.	
	
 
Marker	
Pool	A	 Pool	B	 Pool	C	
µ	±	sd	 CV	(%) µ	±	sd	 CV	(%)	 µ	±	sd	 CV	(%)
CA125	U/ml	
(n=23)	
27.18±	
0.98	 3.59	
36.58±	
1.53	 4.18	
40.36±	
1.88	
4.67	
	
CA15‐3	U/ml	
(n=21)	
15.51±	
0.94	 6.09	
15.68±	
1.02	 6.49	
16.45±	
0.99	
6.00	
	
CA72‐4	U/ml	
(n=15)	 2.37±	0.46 19.45	 1.28±	0.31 24.05	 1.66±	0.38	 22.86	
tPSA	ng/ml	
(n=22)	
0.007±	
0.001	 16.88	
0.003±	
0.001	 38.46	
0.004±	
0.001	 28.87	
PAPP‐A	mIU/L	
(n	=22)	
9.04±	
1.31	 14.47	
6.19±	
1.67	 26.99	
37.15±	
1.69	 4.54	
Marker	 Pooled	Serum	µ	±	sd	 CV	(%)	
CA125	U/ml	(n=25)	 36.20	±	0.90	 2.48	
CA15‐3	U/ml	(n=25)	 15.70	±	0.33	 2.07	
CA72‐4	U/ml	(n=25)	 1.28	±	0.06	 4.68	
tPSA	ng/ml	(n=25)	 0.006	±	0.001	 12.94	
PAPP‐A	mIU/L	(n	=	25)	 9.25	±	0.21	 2.25	
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3.2	Natural	and	Stimulated	Ovarian	Cycles	
3.2.1	Length	of	Follicular	Phase	
The	day	of	ovulation	(as	defined	in	2.1.3.1)	for	the	10	natural	cycles	is	shown	
in	Figure	1	(a).	It	was	extremely	variable,	ranging	from	day	10	to	day	25.	The	
day	of	ovulation	in	the	11	cycles	stimulated	with	exogenous	gonadotrophin	is	
shown	in	Figure	1	(b).	This	was	less	variable	than	the	natural	cycles,	ranging	
between	day	12	and	day	15	of	the	cycle.	
	
3.2.2	Reproductive	Hormones	
The	reproductive	hormone	concentrations	in	natural	and	stimulated	ovarian	
cycles	 are	 shown	 in	 Table	 5.	 In	 the	 early	 follicular	 phase	 the	 oestradiol	
concentrations	 are	 similar	 between	 natural	 (165.6±11.8pmol/L)	 and	
stimulated	cycles	(156.0±6.6pmol/L).	Large	differences	in	oestradiol	are	seen	
by	the	mid‐follicular	phase	where	natural	cycle	concentrations	increase	by	a	
factor	 of	 ~1.6	 times	 to	 an	 average	 of	 265.0±43.0pmol/L	 compared	 to	 an	
increase	by	a	 factor	of	~7.3	 times	 to	an	average	of	1133.7±241.1pmol/L	 in	
stimulated	cycles.	The	oestradiol	concentrations	in	the	late	follicular	phase	in	
natural	 cycles	 on	 average	 doubled	 to	 528.0±51.2pmol/L	 compared	 to	 an	
increase	 by	 a	 factor	 of	 ~3.5	 to	 an	 average	 of	 3980.0±435.8pmol/L	 in	 the	
stimulated	cycles.	Seven	days	after	ovulation	the	oestradiol	concentrations	in	
both	 cycles	 decreased	 slightly	 to	 484.8±68.4pmol/L	 in	 natural	 cycles	 and	
2187.0±301.1pmol/L	in	stimulated	cycles.	
	
Progesterone	 remained	 relatively	 constant	 throughout	 the	 early	 follicular,	
mid‐follicular	 and	 late	 follicular	 phases	 in	 natural	 cycles	 where	
concentrations	 ranged	 from	 1.3±0.2‐1.9±0.3nmol/L.	 It	 wasn’t	 until	 after	
ovulation	during	the	mid‐luteal	phase	that	progesterone	was	seen	to	increase	
in	natural	cycles	(36.5±4.6nmol/L).	Progesterone	was	only	measured	 in	the	
early	 follicular	 and	 mid‐luteal	 phase	 during	 stimulated	 cycles.	 The	
progesterone	concentration	in	stimulated	cycles	(2.3±0.6nmol/L)	was	similar	
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to	 natural	 cycles	 (1.9±0.3	 nmol/L)	 in	 the	 early	 follicular	 phase	 however	
concentrations	 were	 much	 greater	 in	 the	 mid‐luteal	 phase	 of	 stimulated	
cycles	 (197.2±30.0)	 compared	 to	 the	 mid‐luteal	 concentrations	 in	 natural	
cycles	(36.5±4.6).	
	
Table	 5.	 Reproductive	 hormone	 concentrations	 (mean±sem)	 in	
natural	and	stimulated	ovarian	cycles.	The	stage	of	the	cycle	was	
classified	 as	 early	 follicular	 (EF),	 mid‐follicular	 (MF),	 late	
follicular	(LF)	and	mid‐luteal	(ML).	
Stage	
Oestradiol	(pmol/L)	 Progesterone	(nmol/L)	
Natural	 Stimulated	 Natural	 Stimulated	
EF	
MF	
LF	
ML	
165.6±11.8	
265.0±43.0	
528.0±51.2	
484.8±68.4	
156±6.6	
1133.7±241.1	
3980.0±435.8	
2187.0±301.1	
1.9±0.3	
1.4±0.2	
1.3±0.2	
36.5±4.6	
2.3±0.6	
‐	
‐	
197.2±30.0	
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Figure	1.	Day	of	ovulation	 for	women	during	 (a)	Natural	 cycles,	
and	(b)	Stimulated	cycles.	
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3.2.3	 Changes	 in	 serum	 CA125,	 CA15‐3,	 CA72‐4,	 tPSA	 and	 PAPP‐A	
concentrations.	
Serum	 concentrations	 of	 CA125,	 CA15‐3,	 CA72‐4,	 tPSA	 and	 PAPP‐A	 during	
natural	and	stimulated	cycles	are	shown	in	Tables	6	and	7.	When	comparing	
results	from	natural	versus	stimulated	ovarian	cycles,	CA125	concentrations	
showed	 no	 significant	 difference	 (p=0.5989)	 [Table	 8].	 Concentrations	 of	
CA125	 were	 however	 significantly	 influenced	 by	 the	 stage	 of	 the	 ovarian	
cycle	 (p=<0.0001).	 In	natural	menstrual	 cycles,	 the	 concentration	of	 CA125	
was	highest	during	the	early	follicular	phase	of	the	cycle,	which	is	concurrent	
with	menstruation	(25.92±4.45	U/ml)	and	lowest	in	the	late‐follicular	phase	
prior	to	ovulation	(16.76±2.39	U/ml)	[Table	6	&	Appendix	8].	 In	stimulated	
ovarian	 cycles,	 concentrations	of	CA125	were	highest	during	 the	 late	 luteal	
phase	 just	prior	 to	menstruation	(23.57±3.91	U/ml)	and	 lowest	at	 the	mid‐
follicular	phase	(13.41±1.90	U/ml)	[Table	7	&	Appendix	8].	
		
All	 samples	 in	 the	ovarian	 cycles	had	detectable	 levels	of	CA15‐3	 [Tables	6	
and	 7].	 One	 individuals	 sample	 from	 the	 natural	 cycle	 group	 (29.54	 U/ml)	
and	one	from	the	stimulated	group	(29.51	U/ml)	measured	above	the	clinical	
cut‐off	 value	 for	 CA15‐3	 of	 25	U/mL,	 however	 all	 other	 samples	 from	both	
individuals	 were	 below	 the	 clinical	 cut‐off.	 There	 was	 no	 significant	
difference	 in	 the	 CA15‐3	 concentration	 between	 natural	 and	 stimulated	
ovarian	 cycles	 (p=0.8694)	 as	 shown	 in	 Table	 9.	 	 However,	 there	 were	
significant	differences	in	concentrations	seen	between	the	phases	of	the	cycle	
(<0.0001)	[Table	9].	In	natural	menstrual	cycles	the	concentration	of	CA15‐3	
was	highest	in	the	mid‐follicular	phase	(17.52±2.31	U/ml)	and	lowest	in	peri‐
ovulation	(13.67±1.51	U/ml)	[Table	6].	
	
Total	 prostate	 specific	 antigen	 (tPSA)	 was	 detectable	 in	 6/10	 (60%)	 of	
women	 at	 some	 point	 in	 the	 natural	 menstrual	 cycle	 and	 10/11	 (91%)	 of	
women	in	stimulated	cycles.	Concentrations	of	tPSA	were	low	during	natural	
and	 stimulated	 cycles	 and	 there	 was	 no	 significant	 difference	 in	 tPSA	
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concentrations	between	natural	cycles	and	stimulated	cycles	(p=0.9193),	or	
between	 different	 stages	 of	 the	 cycle	 (p=0.8769)	 [Table	 10].	 The	
concentration	of	tPSA	was	highest	in	the	early	follicular	and	late	luteal	phase	
which	 coincides	 with	 menstruation,	 however	 this	 did	 not	 reach	 statistical	
significance	[Table	6].	
	
There	were	 6/10	 (60%)	 of	 the	 individuals	 in	 natural	menstrual	 cycles	 and	
6/11	 (54.5%)	 of	 individuals	 in	 the	 stimulated	 cycles	 that	 had	 detectable	
levels	of	CA72‐4	for	at	least	one	of	the	samples.	CA72‐4	concentrations	were	
overall	on	average	1.47±0.31	U/ml	 in	natural	cycles	and	1.58±0.35	U/ml	 in	
stimulated	ovarian	cycles.	There	was	a	larger	degree	of	variation	between	the	
individuals	 than	 there	 was	 at	 different	 phases	 of	 the	 cycles	 [Table	 6].	 The	
results	 are	 very	 unstable	 and	 inconsistencies	 are	 greatest	 for	 CA72‐4	
compared	to	the	other	biomarkers.			
	
All	samples	had	detectable	levels	of	PAPP‐A	in	natural	and	stimulated	cycles.	
There	was	no	evidence	of	any	significant	changes	in	the	mean	concentration	
of	PAPP‐A	during	natural	and	stimulated	ovarian	cycles	(p=0.4859)	and	there	
was	 no	 evidence	 for	 an	 interaction	 effect	 between	 PAPP‐A	 concentrations	
and	 the	 phase	 of	 the	 cycle	 (p=0.8491)[Table	 11].	 There	 was	 however	 a	
significant	 difference	 in	 PAPP‐A	 concentrations	 in	 the	 natural	 cycles	
compared	to	the	stimulated	cycles	whereby	on	average	the	mean	PAPP‐A	of	
the	natural	group	was	2.41±0.58	mIU/L	higher	than	the	stimulated	group	(p<	
0.0001)[Table	11].		
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Table	 6.	 Biomarker	 concentrations	 (mean	 ±	 sem)	 during	 the	
natural	menstrual	cycle.	
Phase	 CA125	(U/ml)	
CA15‐3	
(U/ml)	
CA72‐4	
(U/ml)	
tPSA	
(ng/ml)	
PAPP‐A	
(mIU/L)	
Early	
Follicular	 25.92±4.45	 15.59±1.67	 1.86±0.92	 0.012±0.009	 8.97±0.79	
Mid‐	
Follicular	 21.36±3.21	 17.52±2.31	 1.21±0.50	 0.007±0.004	 8.91±1.04	
Late‐	
Follicular	 16.76±2.38	 15.91±1.69	 1.10±0.33	 0.009±0.006	 8.59±0.64	
Peri‐
Ovulatory	 17.91±2.64	 13.67±1.51	 2.46±1.47	 0.009±0.006	 9.28±0.90	
Ovulation	 17.49±2.80	 15.26±1.91	 1.65±0.80	 0.008±0.004	 8.8±0.99	
Mid‐Luteal	 20.39±1.83	 16.85±1.94	 1.04±0.31	 0.004±0.002	 8.40±0.81	
Late	Luteal	 19.77±2.51	 15.03±1.95	 1.52±0.96	 0.012±0.006	 8.30±0.89	
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Table	 7.	 Biomarker	 concentrations	 (mean	 ±	 sem)	 during	
stimulated	ovarian	cycles.	
	
	
Table	 8.	 ANOVA	 table	 for	 the	 analysis	 of	 the	 concentration	 of	
CA125	in	natural	and	stimulated	cycles	across	phases.	
	
Phase	 CA125	(U/ml)	
CA15‐3	
(U/ml)	
CA72‐4	
(U/ml)	
tPSA	
(ng/ml)	
PAPP‐A	
(mIU/L)	
Early	
Follicular	 17.06±2.37	 15.10±2.00	 2.33±1.12	 0.0036±0.004 6.24±0.54	
Mid‐	
Follicular	 13.41±1.90	 14.18±2.09	 1.13±0.39	 0.0085±0.002 6.73±0.59	
Late‐	
Follicular	 13.62±1.64	 14.60±1.90	 0.98±0.27	 0.0036±0.003 6.57±0.35	
Mid‐Luteal	 22.89±13.45	 16.99±2.15	 1.72±0.88	 0.0151±0.001 6.19±0.53	
Late	Luteal	 23.57±3.91	 16.84±2.23	 1.53±1.01	 0.0053±0.004 5.97±0.49	
CA125	 numDF	 denDF	 F‐value	 p‐value	
(intercept)	 1	 90	 926.1185	 <0.0001	
Group	 1	 19	 0.2862	 0.5989	
Phase	 1	 90	 6.2613	 0.0141	
Group:phase	 1	 90	 21.5411	 <0.0001	
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Table	 9.	 ANOVA	 table	 for	 the	 analysis	 of	 the	 concentration	 of	
CA15‐3	in	natural	and	stimulated	ovarian	cycles	across	phases.	
	
Table	 10.	 ANOVA	 table	 for	 the	 analysis	 of	 the	 concentration	 of	
Prostate	Specific	Antigen	(tPSA)	in	natural	and	stimulated	ovarian	
cycles	across	phases.	
	
Table	 11.	 ANOVA	 table	 for	 the	 analysis	 of	 the	 concentration	 of	
Pregnancy	Association	Plasma	Protein‐A	(PAPP‐A)	in	natural	and	
stimulated	ovarian	cycles	across	phases.	
	 numDF	 denDF	 F‐value	 p‐value	
(Intercept)	 1	 96	 768.6488	 <.0001	
Group	 1	 25	 56.8412	 <.0001	
Phase	 1	 96	 0.4893	 0.4859	
Group:Phase	 1	 25	 0.8491	 0.8491	
CA15‐3	 numDF	 denDF	 F‐value	 p‐value	
(intercept)	 1	 91	 756.9088	 <0.0001	
Group	 1	 19	 0.0278	 0.8694	
Phase	 1	 91	 35.4565	 <0.0001	
Group:phase	 1	 91	 23.0392	 <0.001	
PSA	 numDF	 denDF	 F‐value	 p‐value	
(intercept)	 1	 67	 734.6268	 <0.0001	
Group	 1	 14	 0.0107	 0.9193	
Phase	 1	 67	 0.0157	 0.9006	
Group:phase	 1	 67	 0.0242	 0.8769	
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3.3	Early	Pregnancy	
3.3.1	Reproductive	hormones	
The	 serum	 hCG	 concentrations	 increased	 from	 296.8±70.9	 at	 4	 weeks	 to	
52191.3±11310.7	 at	 7	weeks	 [Table	 12].	 This	 increase	 in	 hCG	during	 early	
pregnancy	 is	 highly	 significant	 (p=<0.0001)	 [Table	 13].	 Progesterone	
concentrations	 were	 steady	 ranging	 from	 179.2±42.1	 at	 week	 4	 to	
287.8±78.8	at	week	7	of	gestation	[Table	12].	
 
3.3.2	Serum	PAPP‐A,	CA125,	CA15‐3,	CA72‐4	and	tPSA.		
The	PAPP‐A,	CA125,	CA15‐3,	CA72‐4	and	tPSA	biomarker	concentrations	are	
shown	 in	 Table	 17.	 The	 concentration	 of	 PAPP‐A	 increased	 steadily	 from	
6.51±0.56mIU/L	at	4	weeks	 to	125.38±54.2mIU/L	at	7	weeks.	The	 changes	
seen	 in	 early	 pregnancy	 were	 highly	 significant	 (p=<0.0001)	 for	 PAPP‐A	
[Table	14]	and	all	pregnancies	were	viable	and	resulted	in	a	live	birth.		
	
The	 concentrations	 of	 CA125	 in	 early	 pregnancy	 are	 shown	 in	 Table	 18.	
There	 was	 a	 significant	 effect	 of	 the	 stage	 of	 gestation	 on	 CA125	
concentration	 (p=0.0012)	 [Table	 15	 &	 Appendix	 9].	 However,	 there	 was	
considerable	 variability	 in	 the	 timing	 of	 peak	 CA125	 [Figure	 2].	When	 the	
values	 are	normalised	 to	 the	 time	of	peak	value	 there	 are	 clear	patterns	of	
change	in	CA125	concentration	[Figure	3].		
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Figure	2.	A	frequency	distribution	of	the	time	of	peak	CA125	
concentration	for	14	pregnant	women.		
 
 
Figure	3.	The	serum	CA125	concentration	(U/ml)	relative	to	the	
time	of	the	peak	concentration	for	14	pregnant	women.	
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There	were	9/14	(64%)	of	the	pregnant	women	that	had	detectable	levels	of	
tPSA	in	at	least	one	sample	during	early	pregnancy.	The	concentration	of	PSA	
increased	steadily	 from	0.005±0.001	at	4	weeks	 to	0.01	±	0.003	at	7	weeks	
[Table	18	&	Appendix	9],	with	an	average	increase	of	0.0015	±	0.0004ng/ml	
for	every	one	unit	increase	in	gestation	time	(p=0.000	)	[Table	16].	In	effect,	
the	concentration	of	tPSA	in	maternal	serum	on	average	doubled	from	week	
four	to	seven	of	gestation.		
	
All	participants	had	detectable	levels	of	CA15‐3	throughout	early	pregnancy	
where	 there	was	a	significant	effect	of	 the	stage	of	gestation	on	 the	CA15‐3	
concentration	(p=0.000)	[Table	17	&	Appendix	9].	The	average	concentration	
of	 CA15‐3	 was	 16.44±2.22U/ml	 at	 4	 weeks	 gestation	 and	 over	 the	 time	
period	 reduced	 to	 an	 average	 of	 12.97±2.35U/ml	 [Table	 17].	 These	
concentrations	were	all	below	the	clinical	cut‐off	value	of	25U/ml.			
	
Of	 the	 participants,	 only	 57%	of	women	 in	 early	 pregnancy	 had	 detectable	
levels	of	CA72‐4	 for	at	 least	one	of	 their	samples.	The	clinical	cut‐off	values	
for	CA72‐4	are	variable	 and	 transferability	of	 expected	values	 to	 individual	
laboratories	 can	 be	 considerably	 different.	 	 The	 CA72‐4	 concentration	 in	
pregnancy	was	on	average	2.14±3.5U/ml,	however,	because	of	the	variability	
of	 results	 both	 within‐individuals	 and	 between‐individuals	 a	 statistical	
analysis	was	not	 performed	 as	 the	 distribution	did	 not	 fit	 the	 linear	mixed	
effects	model.	
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Table	12.	Reproductive	hormone	 concentrations	 (mean±sem)	 in	
early	pregnancy	according	to	the	gestational	age.	
Gestation	
Hormone	Concentrations	
Oestradiol	
(pmol/L)	
Progesterone	
(nmol/L)	 hCG	(IU/L)	
4	weeks	
4.5	weeks	
5	weeks	
5.5	weeks	
6	weeks	
6.5	weeks	
7	weeks	
1797.5±394.3	
‐	
‐	
‐	
‐	
‐	
‐	
179.2±42.1	
179.7±43.5	
179.3±37.2	
196.8±43.4	
169.3±34.9	
167.9±42.5	
287.8±78.8	
296.8±70.9	
1773.0±262.0	
5359.6±1212.8	
15085.9±2666.5	
31725.0±5367.8	
48306.0±7371.0	
52191.3±11310.7	
	
Table	13.	ANOVA	table	for	the	linear	mixed	effects	model	for	hCG	
levels	during	pregnancy.	
	
Table	 14.	 ANOVA	 table	 for	 the	 linear	 mixed	 effects	 model	 for	
PAPP‐A	levels	during	pregnancy.	
hCG	 numDF	 denDF	 F‐value	 p‐value	
(Intercept)	 1	 69	 5634.490	 <0.0001	
Gestation	 1	 69	 1153.922	 <0.0001	
PAPP‐A	 numDF	 denDF	 F‐value	 p‐value	
(Intercept)	 1	 69	 1094.4500	 <0.0001	
Gestation	 1	 69	 549.0459	 <0.0001	
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Table	 15.	 ANOVA	 table	 for	 the	 linear	 mixed	 effects	 model	 for	
CA125	levels	during	pregnancy.	
	
	
Table	 16.	 ANOVA	 table	 for	 the	 linear	 mixed	 effects	 model	 for	
Prostate	Specific	Antigen	(tPSA)	levels	during	pregnancy.	
	
	
Table	 17.	 ANOVA	 table	 for	 the	 linear	 mixed	 effects	 model	 for	
CA15‐3	levels	during	pregnancy.	
CA125	 numDF	 denDF	 F‐value	 p‐value	
(Intercept)	 1	 69	 207.11741	 <0.0001	
Gestation	 1	 69	 11.38667	 0.0012	
PSA	 numDF	 denDF	 F‐value	 p‐value	
(Intercept)	 1	 45	 2967.6833	 <0.0001	
Gestation	 1	 45	 15.6762	 0.000	
CA15‐3	 numDF	 denDF	 F‐value	 p‐value	
(Intercept)	 1	 69	 528.8371	 <0.0001	
Gestation	 1	 69	 15.7576	 0.000	
                                                                                                     
 
Table.18	Biomarker	concentrations	(mean	±	sem)	during	early	pregnancy.		
Gestation	
(Weeks)	
CA125	
(U/ml)	
CA15‐3	
(U/ml)	
CA72‐4	
(U/ml)	
tPSA	
(ng/ml)	
PAPP‐A	
(mIU/ml)	
4	
(n=7‐9)	
22.79	
±3.73	
16.44	
±2.22	
2.15	
±1.08	
0.005	
±0.001	
6.51	
±0.56	
4.5	
(n=9‐14)	
30.40	
±6.02	
15.19	
±1.56	
2.19	
±1.05	
0.005	
±0.001	
6.86	
±0.40	
5	
(n=9‐14)	
47.65	
±15.12	
14.59	
±1.60	
2.42	
±1.24	
0.006	
±0.001	
8.29	
±0.66	
5.5	
(n=9‐14)	
57.98	
±27.45	
14.30	
±1.58	
2.15	
±1.08	
0.007	
±0.001	
14.58	
±1.47	
6	
(n=9‐14)	
48.15	
±19.13	
14.28	
±1.54	
1.68	
±0.66	
0.008	
±0.001	
34.41	
±4.45	
6.5	
(n=8‐13)	
42.59	
±10.56	
14.04	
±1.53	
1.79	
±0.74	
0.009	
±0.001	
59.37	
±7.09	
7	
(n=4‐6)	
29.92	
±6.44	
12.97	
±2.35	
2.60	
±1.40	
0.010	
±0.003	
125.38	
±22.11	
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4.0	 Discussion	
4.1	Assay	Characteristics	 	
The	use	of	immunoassays	allows	precise	quantitative	measurements	to	be	made	
when	 measuring	 analytes.	 However,	 different	 assays	 often	 have	 different	
characteristics	 due	 to	 the	 choice	 of	 reagent	 or	 their	 calibration,	 resulting	 in	
different	 numerical	 values.	 This	 is	 important	 when	 comparing	 work	 from	
various	laboratories	or	over	a	range	of	time	frames.	For	example,	the	expression	
of	PAPP‐A	results	in	mIU/ml	in	the	present	study	compared	to	µg/L	elsewhere	
(Sinosich,	Porter,	Sloss,	Bonifacio,	&	Saunders,	1984;	Yovich	et	al.,	1986)	reflects	
the	 change	 in	 methodology	 and	 the	 move	 to	 a	 different	 standardisation.		
Between‐assay	 differences	 have	 been	 reported	 when	measuring	 CA15‐3	 with	
commercial	 kits	 from	 different	 companies,	 resulting	 from	 differences	 in	 the	
antibodies	 produced	 against	 different	 sections	 of	 the	 antigen	 as	 well	 as	
calibration	rather	than	specificity	(Klee	&	Schreiber,	2004).	This	is	perhaps	not	
too	 surprising	 as	 many	 of	 the	 companies	 used	 similar	 capture	 and	 signal	
antibodies	 in	 their	 sandwich	 immunometric	 assays.	 Different	 CA125	 assays	
have	used	different	reference	preparations,	such	that	results	are	then	expressed	
in	different	units.	Whilst	the	current	study	used	an	assay	with	results	 in	U/ml,	
Tavmergen	et	al.	(2001)	used	a	method	reporting	in	IU/ml.		The	performance	of	
the	 CA125	 assays	 can	 also	 show	 between‐supplier	 variability,	 and	 large	
differences	 have	 been	 reported	 between	 assays	 supplied	 by	 Siemens	 and	
Panomics	(McLemore	et	al.,	2012).	
	
Secondary	to	 the	variation	seen	between	the	assays	used	 in	different	research	
projects,	 there	 is	 also	 some	variation	 associated	with	using	 the	 same	assay	 in	
different	runs.	The	between‐batch	assay	variation	differs	amongst	analytes	and	
so	 it	 is	 important	 to	 assess	 the	 between‐batch	 variation	 associated	 with	 the	
method	being	used	to	ensure	that	any	changes	seen	are	the	result	of	biological	
fluctuations	 and	 not	 because	 of	 the	 assay	 variation.	 In	 this	 present	 study	 the	
between‐batch	variation	was	further	compared	with	the	within‐batch	variation	
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to	ensure	that	the	method	used	only	had	the	smallest	assay	variation	associated	
with	 the	 results.	 The	 assessment	of	 the	 between‐batch	 variation	was	done	by	
measuring	artificial	 quality	 control	 (QC)	material	 from	both	 the	 company	 that	
manufactures	the	assay	and	an	external	source	on	up	to	45	different	occasions.	
Along	 with	 the	 manufactured	 QC	 samples,	 pooled	 human	 serum	 was	 also	
analysed	to	assess	the	assays	at	levels	found	in	our	study	population.		
	
The	results	for	the	between‐batch	variation	measured	using	the	commercial	QC	
material	 showed	 good	 reproducibility	 for	 the	 CA125	 and	 CA15‐3	 assays	
however	 the	 PAPP‐A,	 tPSA	 and	 CA72‐4	 assays	 showed	 considerably	 greater	
variability.	The	results	obtained	using	the	pooled	human	serum	showed	similar	
patterns	for	CA125	and	CA15‐3	however	again	the	lower	concentrations	of	the	
tPSA,	 CA72‐4	 and	 PAPP‐A	 in	 the	 pooled	 human	 serum	 resulted	 in	 a	 larger	
degree	of	variability.	The	results	for	the	within‐batch	variation	measured	using	
the	pooled	human	serum	show	good	reproducibility	whereby	the	within‐batch	
variation	 for	 CA125,	 CA15‐3,	 CA72‐4	 and	PAPP‐A	 all	 show	CVs	 of	 <5.0%.	The	
within‐batch	results	for	tPSA	were	more	variable	than	the	other	assays	however	
the	serum	concentrations	for	tPSA	are	lower	in	females	and	thus	near	the	assays	
lower	 limit	 of	 detection.	 The	 difference	 in	 the	 between‐batch	 variation	 and	
within‐batch	 variation	 shows	 that	 the	 analysis	 of	 longitudinal	 samples	 from	
individual	women	 should	 be	 done	 in	 one	 batch	 analysis	where	 possible.	 This	
ensures	that	any	changes	seen	in	the	concentrations	of	the	biomarkers	are	due	
to	biological	fluctuations	and	it	reduces	the	interference	that	might	be	the	result	
of	the	assay	itself.	
   
4.2	Ovarian	Cycles	
The	lengths	of	the	follicular	phase	in	the	natural	cycles	included	in	this	present	
study	 were	 variable	 ranging	 between	 10‐25	 days.	 This	 is	 similar	 to	 previous	
work	performed	by	Cole	et	al.	(2009)	which	showed	the	distribution	of	the	LH	
peak	 as	 being	 between	10‐20	days,	 and	Lenton,	 Landgren,	 and	 Sexton	 (1984)	
who	reported	a	distribution	of	8.2‐21	days.	The	range	of	lengths	of	the	follicular	
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phase	in	stimulated	cycles	was	less,	being	between	12‐15	days	as	they	were	all	
controlled	 ovarian	 cycles	 and	 the	 differences	 in	 days	 is	 attributable	 to	 the	
individual	response	to	the	stimulation	protocol.	The	hormone	levels	in	all	cycles	
followed	 the	 classical	 patterns	 of	 change,	 confirming	 that	 the	 modelling	 and	
expression	of	results	according	to	the	stage	of	cycle	is	appropriate.		
	
There	were	 phase	 dependent	 changes	 seen	 in	 CA125	 concentrations	 for	 both	
natural	 and	 stimulated	 ovarian	 cycles.	 This	 study	 showed	 that	 there	 was	 no	
effect	 of	 ovarian	 hyperstimulation	 on	 CA125	 levels	 and	 that	 both	 natural	 and	
stimulated	ovarian	 cycles	 showed	 similar	 changing	patterns.	 The	 results	 from	
the	 natural	 group	 agreed	with	 the	 literature	 in	 that	 the	 highest	 CA125	 levels	
were	found	during	menstruation	(Bon	et	al.,	1999;	Haga	et	al.,	1986;	Jager	et	al.,	
1988;	McLemore	et	al.,	2012;	Pittaway	&	Fayez,	1987;	Touitou	et	al.,	1989).The	
stimulated	 group	 results	 also	 agreed	 with	 the	 literature	 where	 the	 highest	
CA125	levels	were	found	in	the	luteal	phase	of	the	cycle	(Zweers	et	al.,	1990).	It	
was	suggested	that	CA125	levels	were	negatively	correlated	to	oestradiol	levels	
however	the	lack	of	difference	between	stimulated	and	natural	cycles	suggests	
that	 even	 with	 grossly	 elevated	 oestradiol	 levels,	 there	 is	 no	 significant	
difference	in	CA125	concentrations.	This	would	also	confirm	reports	that	it	is	in	
fact	 the	 endometrium	 that	 is	 responsible	 for	 the	 cyclical	 changes	 in	 CA125	
concentrations	and	it	is	the	disruption	of	the	endometrium	during	menses	that	
allows	increased	amounts	of	CA125	to	enter	the	blood	stream	(Bon	et	al.,	1999;	
Kafali	 et	 al.,	 2007;	Weintraub,	 Bischof,	 Tseng,	 Redard,	 &	 Vassilakos,	 1990).	 It	
was	also	proposed	that	pregnancy	outcomes	following	ART	treatment	could	be	
predicted	 by	measuring	 CA125	 on	 the	 day	 of	 oocyte	 retrieval	 and	 that	 levels	
>10IU/ml	were	 correlated	with	 an	 86.6%	positive	 pregnancy	 rate	 based	 on	 a	
prospective	 study	 of	 75	 ART	 cycles	 (Tavmergen	 et	 al.,	 2001).	 Of	 the	 8	
participants	in	this	study	that	had	a	CA125	of	>10U/ml	before	oocyte	retrieval,	
only	 3	 of	 those	 became	 pregnant	 (37.5%)	 which	 is	 markedly	 lower	 than	 the	
literature	had	suggested.	There	was	also	one	participant	who	had	a	CA125	level	
<10U/ml	that	did	become	pregnant.	Although	these	results	are	interesting	they	
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are	 limited	 by	 the	 relatively	 small	 sample	 size	 but	 may	 warrant	 further	
investigation.	
	
Serum	 concentrations	 of	 CA15‐3	 in	 natural	 menstrual	 cycles	 were	 not	
statistically	different	to	those	found	in	stimulated	cycles	suggesting	that	ovarian	
stimulation	per	se	 for	 the	purposes	of	 IVF	and	ICSI	procedures	does	not	affect	
circulating	serum	CA15‐3	 levels.	The	CA15‐3	concentration	did	however	show	
some	interaction	with	the	phases	of	 the	cycles	which	 is	 in	agreement	with	the	
literature	(Erbagci,	Yilmaz,	&	Kutlar,	1999).	The	MUC1	gene,	which	encodes	the	
CA15‐3	glycoprotein,	is	expressed	in	the	upper	female	reproductive	tract	and	its	
function	has	been	suggested	to	be	to	prevent	ectopic	embryo	implantation	(Al‐
Azemi	 et	 al.,	 2009).	 Other	 studies	 have	 shown	 that	 MUC1	 expression	 is	
progesterone	 dependent	whereby	 it	 is	 up	 regulated	 in	 the	 luteal	 phase	 of	 the	
menstrual	cycle	(Aplin,	Hey,	&	Graham,	1998;	Hey,	Graham,	Seif,	&	Aplin,	1994).	
These	 findings	 are	 fitting	because	 if	MUC1	 is	up	 regulated	by	progesterone	 in	
the	 luteal	 phase,	 it	 would	 suggest	 that	 it	 is	 indeed	 a	 part	 of	 the	 body’s	
mechanisms	 to	 avoid	 ectopic	 pregnancy.	 This	 current	 study	 has	 shown	 that	
serum	concentrations	of	CA15‐3	are	at	their	highest	in	the	mid‐follicular	phase	
of	 the	 natural	 menstrual	 cycle,	 which	 is	 at	 a	 time	 that	 progesterone	 is	 at	 its	
lowest	levels,	suggesting	that	although	CA15‐3	is	encoded	by	the	MUC1	gene,	it	
does	 not	 appear	 to	 be	 progesterone	 dependent.	 This	 being	 said,	 the	 previous	
research	on	MUC1	expression	was	carried	out	on	tissue	samples	whereas	this	is	
an	analysis	of	serum	concentrations	so	the	‘lag’	in	peak	CA15‐3	concentrations	
may	not	reflect	activity	at	a	local	level.	
	
Prostate	 specific	 antigen	 (PSA)	 was	 thought	 to	 be	 produced	 exclusively	 by	
prostatic	 tissue	 and	 was	 therefore	 used	 to	 monitor	 prostate	 cancer	
(Armbruster,	1993).	However,	 it	has	been	associated	with	a	number	of	tissues	
and	 biological	 events	 in	women	 (EP	Diamandis	&	H	 Yu,	 1995)	 such	 as	 in	 the	
breast	(He	Yu	et	al.,	1996)	and	during	the	ovarian	cycle	(Aksoy,	Akçay,	Umudum,	
Yildirim,	 &	 Memisogullari,	 2002;	 N.	 Zarghami,	 L.	 Grass,	 E.	 R.	 Sauter,	 &	 E.	 P.	
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Diamandis,	 1997).	 Total	 prostate‐specific	 antigen	 was	 detectable	 in	 60%	 of	
women	in	natural	cycles	and	91%	of	women	during	stimulated	ovarian	cycles.	
The	 range	 of	 mean	 results	 from	 each	 phase	 was	 between	 0.004ng/ml	 –	
0.012ng/ml	 for	 both	 natural	 and	 stimulated	 ovarian	 cycles.	 There	 was	 no	
significant	relationship	between	tPSA	concentration	and	phase	of	the	cycle,	nor	
was	there	any	significant	difference	between	tPSA	concentrations	in	natural	and	
stimulated	cycles.	Zarghami	et	al.,	 (1997)	 indicated	that	 tPSA	in	the	menstrual	
cycle	 followed	 the	 progesterone	 concentration	 peak	 with	 a	 10‐12	 day	 delay	
which	 was	 suggestive	 that	 tPSA	 changed	 in	 a	 cyclical	 manner.	 This	 present	
study	 shows	 that	 tPSA	 concentrations	were	highest	 in	 the	 early	 follicular	 and	
late	 luteal	phase	which	 is	relative	 to	menstruation	although	this	did	not	reach	
statistical	 significance.	 Total	 prostate	 specific	 antigen	 concentrations	 are	 very	
low	 in	 female	 serum	and	 it	 is	 not	 known	why	 some	women	have	measurable	
levels	of	tPSA	and	others	do	not.	The	physiological	function	of	tPSA	in	females	is	
yet	to	be	determined.	
	
Ohuchi	 et	 al.	 (1989)	 described	 CA72‐4	 as	 a	 useful	 tumour	 marker	 for	 all	
tumours	 derived	 from	 epithelial	 cells	 highlighting	 the	 tumour	 markers	
increased	 sensitivity	 to	 gastric	 carcinoma	 compared	 to	 other	 tumour	markers	
such	as	CA19‐9,	CEA	and	CA125.		It	was	also	proposed	that	when	CA72‐4	is	used	
as	a	complimentary	biomarker	to	CA125,	the	sensitivity	for	detecting	early	stage	
ovarian	 cancer	 increased	 from	45%	 to	 70%	 (Skates	 et	 al.,	 2004).	 The	 CA72‐4	
assay	used	in	this	research	failed	to	register	any	results	above	the	assays	lower	
limit	of	detection	in	40‐45.5%	of	 individuals	from	both	natural	and	stimulated	
ovarian	 cycles.	Of	 those	 individuals	 that	 did	 have	detectable	 levels	 of	 CA72‐4,	
the	 results	 showed	 an	 extremely	 high	 degree	 of	 variability	 both	 within	 each	
individual	(whereby	each	sample	from	the	same	cycle	was	vastly	different	to	the	
others)	and	between	patients	where	the	difference	was	so	large	that	there	were	
no	obvious	patterns	of	change.	It	was	for	these	reasons	that	statistical	analysis	
was	not	carried	out	and	it	was	concluded	that	the	assay	was	too	unreliable	for	
use	as	a	diagnostic	measure	in	the	clinical	setting.		
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Similar	 to	 the	 misnomer	 with	 PSA,	 the	 name	 pregnancy‐associated	 plasma	
protein‐A	 (PAPP‐A)	 does	 not	 necessarily	mean	 this	 protein	 is	 associated	 only	
with	pregnancy.	Although	most	 of	 the	 research	 surrounding	PAPP‐A	has	been	
performed	 during	 pregnancy	 (D'Antonio	 et	 al.,	 2013;	 Dane	 et	 al.,	 2013;	
Folkersen	et	al.,	1981;	 Jacobs	et	al.,	1990;	Lin	et	al.,	1974;	NJ	Wald,	Hackshaw,	
Diamandis,	&	Melegos,	1999;	Yovich	et	al.,	1986),	there	are	recent	studies	which	
indicate	 differences	 in	 PAPP‐A	 concentrations	 during	 ART	 treatment	 cycles	
(bAmor	 et	 al.,	 2009;	 Maymon	 &	 Shulman,	 2002b;	 Orlandi	 et	 al.,	 2002;	 Tul	 &	
Novak‐Antolic,	 2006).	 This	 present	 study	 found	 a	 significant	 difference	 in	 the	
mean	concentration	of	PAPP‐A	between	natural	and	stimulated	ovarian	cycles,	
where	stimulated	ovarian	cycles	were	on	average	2.41±0.58mIU/L	 lower	 than	
natural	cycles.	The	present	study	also	showed	that	throughout	each	of	the	two	
types	of	cycles	there	were	no	significant	changes	 in	PAPP‐A	levels.	Findings	of	
lower	serum	PAPP‐A	concentrations	in	women	during	stimulated	ovarian	cycles	
confirms	 previous	 work	 where	 it	 was	 shown	 that	 women	 had	 lower	 serum	
PAPP‐A	levels	with	higher	oocyte	number	after	oocyte	retrieval,	 leading	to	the	
proposal	that		differences	in	PAPP‐A	concentrations	may	be	due	to	the	presence	
of	multiple	corpora	lutea	in	the	ovaries	(Tul	&	Novak‐Antolic,	2006).	Amor,	et	al.	
(2009)	found	that	PAPP‐A	levels	were	reduced	in	both	fresh	and	frozen‐thawed	
embryo	transfers	when	compared	to	naturally	conceived	pregnancies,	however,	
fresh	 transfers	did	have	 significantly	 lower	PAPP‐A	 levels	 than	 frozen‐thawed	
transfers.	 This	 again	 provides	 evidence	 for	 the	multiple	 corpora	 lutea	 theory	
where	 the	 ovaries	 in	 frozen‐thawed	 embryo	 transfer	 cycles	 are	 not	
hyperstimulated	 to	 create	 multiple	 follicle	 development	 like	 those	 of	 fresh	
cycles.	 Similar	 to	 the	 literature	 which	 states	 that	 PAPP‐A	 concentrations	 are	
similar	between	ART	subtypes,	this	present	study	also	found	that	there	was	no	
significant	 difference	 between	 the	 PAPP‐A	 concentrations	 in	 IVF	 versus	 ICSI	
cycles.	
	
4.3	Early	Pregnancy	
All	 fourteen	 of	 the	 pregnancies	 included	 in	 this	 study	 resulted	 in	 a	 live	 birth	
with	 no	 complications.	 The	 reproductive	 hormone	 levels	 in	 all	 individuals	
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followed	the	classical	pattern	of	change	throughout	early	pregnancy,	confirming	
that	 the	 modelling	 used	 to	 express	 the	 results	 according	 to	 the	 timing	 of	
gestation	 was	 appropriate.	 The	 progesterone	 levels	 were	 maintained	 at	 a	
constant	level	via	the	administration	of	progesterone	pessaries	which	aid	in	the	
support	of	the	pregnancy.	
	
	There	 have	 been	 many	 publications	 (Aslam	 et	 al.,	 2000;	 Halila	 et	 al.,	 1986;	
Kobayashi	et	al.,	1993;	Niloff	et	al.,	1984;	Pittaway	&	Fayez,	1987)	where	CA125	
has	been	measured	and	 found	to	 increase	during	pregnancy;	however	most	of	
these	 are	 reports	 from	 cross	 sectional	 studies	 that	 compare	 single	 CA125	
measurements	from	each	of	the	gestational	trimesters.	This	study	was	different	
in	that	serial	blood	samples	were	collected	from	the	same	women	from	4	weeks	
gestation	 through	until	 seven	weeks	gestation.	As	 the	women	 in	 this	 study	all	
fell	pregnant	following	ART	treatment,	important	events	such	as	ovulation	were	
known	and	implantation	could	be	inferred	from	this	timing.	Pregnancy	tests	are	
done	 fourteen	 days	 after	 ovulation	 is	 confirmed,	 which	 is	 also	 referred	 to	 in	
obstetrics	as	4	weeks	gestation	relative	to	the	last	menstrual	period.	This	study	
found	 that	 in	 early	 pregnancy	 CA125	 levels	 were	 generally	 lower	 than	 the	
clinical	 cut‐off	 value	 at	 week	 4,	 however	 they	 did	 increase	 significantly	 on	
average	at		week	5.5	before	reducing	again	back	to	the	normal	range	by	week	7.	
It	was	observed	that	although	the	statistical	mean	for	peak	concentrations	was	
week	 5.5,	 there	was	 a	 degree	 of	 variation	 on	 the	 time	 of	 gestation	 that	 these	
peak	 levels	 did	 actually	 occur.	 It	 showed	 that	 there	 were	 two	 time	 points,	
namely	 week	 5	 and	 6.5	 that	 had	 more	 individuals	 have	 their	 peak	 CA125	
concentration.	This	 being	 said,	 although	different	women	had	different	 timing	
for	elevated	CA125	concentrations,	when	the	data	was	standardised	so	that	all	
concentration	 peaks	 were	 labelled	 as	 t=0	 and	 the	 other	 samples	 were	 timed	
accordingly,	 the	 same	 significant	 changes	 in	CA125	 concentrations	were	 seen.	
This	elevation	of	CA125	is	concurrent	with	placentation	events	occurring	in	the	
endometrium	 and	 along	 with	 previous	 suggestions	 that	 circulating	 CA125	 is	
attributable	to	endometrium	disruption	during	menses,	 it	would	suggest	again	
that	 it	 is	 the	 disruption	 of	 the	 endometrium	 during	 placentation	 that	may	 be	
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responsible	 for	 this	 elevation.	 There	 have	 been	 other	 studies	 suggesting	 that	
pregnancies	with	 elevated	CA125	 (>65U/ml)	 in	 the	 first	 trimester	were	 at	 an	
increased	risk	of	 spontaneous	abortion	however	 in	 successful	pregnancies	 the	
CA125	 reduced	 to	 <93U/ml	 between	 weeks	 7‐12	 gestation,	 although	 those	
pregnancies	which	did	abort	still	had	levels	>120U/ml	(Azogui	et	al.,	1996;	Ocer	
et	 al.,	 1992).	 The	 current	 study	 had	 four	 pregnant	 participants	 that	 had	 peak	
CA125	 levels	 between	 94‐341U/ml	 where	 all	 pregnancies	 resulted	 in	 a	 live	
birth.	 Of	 these	 four	 pregnancies	with	 elevated	 CA125,	 all	 but	 one	 reduced	 to	
<93U/ml	by	week	7,	however	 the	one	participant	whose	CA125	did	not	 reach	
<93U/ml	had	her	last	sample	collected	at	week	6.5	gestation	so	it	is	not	known	
if	this	would	have	reduced	further	or	not.	The	results	 in	this	study	do	seem	to	
follow	 the	 trends	 highlighted	 in	 previous	 work	 and	 would	 agree	 with	 the	
argument	that	as	a	predictor	of	spontaneous	abortion,	an	elevated	CA125	level	
is	an	 indicator	of	 the	decidual	destruction	which	 is	associated	with	pregnancy	
outcome	(Ocer	et	al.,	1992).	
	
During	early	pregnancy	there	was	a	significant	effect	of	the	stage	of	gestation	on	
CA15‐3	 concentrations,	 where	 the	 CA15‐3	 concentrations	 declined	 as	 the	
pregnancy	progressed	to	week	7.	Other	studies	reported	in	the	literature	have	
used	 cross‐sectional	 samples	 collected	 later	 in	 pregnancy,	 and	 have	 shown	
CA15‐3	 to	 increase	 towards	 delivery,	 being	higher	 in	 the	 third	 trimester	 than	
first	 and	 second	 trimesters	 using	 (Bon	 et	 al.,	 2001;	 Correale	 et	 al.,	 1993).	
Research	by	Meseguer	et	 al.	 (2001)	 found	 that	 the	MUC1	gene	which	encodes	
CA15‐3	is	an	anti‐adhesive	molecule	that	is	expressed	on	endometrial	epithelial	
cells	and	the	human	blastocyst.	The	study	also	found	that	there	was	an	increase	
in	 the	MUC1	expression	during	 the	 apposition	phase	of	 implantation	 followed	
by	 a	 localised	 down	 regulation	 of	 MUC1	 during	 adhesion	 at	 the	 site	 of	
implantation.	 In	 the	 present	 study,	 serum	 concentrations	 of	 CA15‐3	 decrease	
from	week	four	to	week	seven	of	gestation	which	is	suggestive	that	the	declining	
serum	 concentrations	 of	 CA15‐3	 might	 be	 a	 potential	 biomarker	 of	 certain	
implantation	events	and	warrants	further	investigation.	
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Prostate	specific	antigen	was	detectable	in	9/14	(64%)	of	the	pregnant	women	
in	this	study.	 In	 these	women,	PSA	on	average	 increased	steadily	 from	week	4	
through	week	 7	 of	 gestation	where	 concentrations	 effectively	 doubled.	 There	
have	 not	 been	 any	 studies	 that	 indicate	 the	 behaviour	 of	 PSA	 this	 early	 in	
pregnancy	 	 however	 other	 literature	 does	 confirm	 that	 PSA	 in	 amniotic	 fluid	
increased	from	weeks	11	to	21	and	thereafter	declined	until	birth	(H.	Yu	et	al.,	
1995).	 Prostate	 specific	 antigen	 is	 expressed	 by	 normal,	 hyperplastic	 and	
neoplastic	female	breast	tissue	so	 it	was	of	 interest	to	measure	PSA	in	women	
during	 early	 pregnancy	when	 breast	 changes	 can	 occur.	 The	 PSA	was	 seen	 to	
increase	significantly	in	some	women	whilst	the	breast	tumour	marker	CA15‐3	
when	measured	 in	 the	 same	women	decreased.	 It	would	 then	appear	 that	 the	
PSA	circulating	in	the	serum	is	not	of	the	same	origin	as	CA15‐3,	and	the	role	of	
PSA	 as	 a	 marker	 of	 normal	 embryo	 implantation	 and	 development	 warrants	
further	study.		
	
With	increasing	numbers	of	pregnancies	being	achieved	through	ART	and	much	
research	 into	 the	 risks	 associated	with	 a	pregnancy	achieved	 from	ART,	 there	
have	been	many	reports	that	PAPP‐A	levels	at	the	first	trimester	screening	are	
reduced	compared	to	those	conceived	naturally.	As	PAPP‐A	is	measured	as	part	
of	 the	 Down	 syndrome	 screening	 tests,	 an	 increase	 in	 the	 false	 positive	 rate	
would	 mean	 an	 increase	 in	 the	 number	 of	 unnecessary	 amniocentesis	
procedures	 being	 carried	 out	 on	 these	 already	 precious	 pregnancies.	 The	
present	study	measured	PAPP‐A	levels	during	the	first	vital	weeks	of	pregnancy	
until	 week	 seven	 of	 gestation	 with	 the	 intention	 of	 giving	 insight	 into	 the	
behaviour	 of	 PAPP‐A	 during	 this	 time	 period.	 It	 was	 found	 that	 PAPP‐A	
concentrations	 increased	 steadily	 from	 6.51±0.56mIU/ml	
to125.38±22.11mIU/ml	by	week	7,	where	 levels	 at	week	 four	were	 similar	 to	
those	found	throughout	the	stimulated	ovarian	cycles.	These	pregnancies	were	
all	conceived	following	ART	treatment	which	would	explain	the	similar	PAPP‐A	
levels	at	week	four	of	gestation.	
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Although	 described	 as	 a	 useful	 biomarker	 of	 various	 different	 conditions	
(Ohuchi	et	al.,	1989),	CA72‐4	concentrations	in	this	population	of	women	were	
extremely	variable.	The	results	in	the	group	of	pregnant	women	showed	a	high	
degree	 of	 variability	 within	 each	 of	 the	 individuals	 however	 there	 were	 no	
obvious	patterns	of	change.	Close	to	half	(43%)	of	the	women	in	this	study	did	
not	 have	 detectable	 levels	 of	 CA72‐4,	 where	 the	 lower	 limit	 of	 detection	 is	
<0.2U/ml.	It	was	for	this	reason	that	statistical	analysis	was	not	carried	out	and	
the	assay	was	deemed	too	unreliable	for	use	in	the	clinical	setting.	
		
4.4	Crossing	of	Clinical	Thresholds	
Whilst	many	 biomarkers	may	 be	 associated	with	 the	 underlying	 process	 of	 a	
disease,	 there	can	be	many	ways	 in	which	 the	use	of	 the	biomarker	may	have	
limited	 clinical	 utility	 (Palmer	 &	 Barnhart,	 2013).	 This	 can	 be	 seen	 with	
biomarkers	that	were	once	used	routinely	in	diagnostic	medicine	and	originally	
thought	to	be	specific	to	particular	diseases,	but	have	subsequently	been	shown	
to	either	(a)	have	a	limited	response	in	some	individuals	despite	the	presence	of	
the	 disease	 or	 (b)	 be	 associated	with	 other	 biological	 processes	 and	 possibly	
cloud	 the	 interpretation.	 A	 good	 example	 of	 the	 former	 is	 tPSA	 and	 prostate	
cancer	where	the	measurement	of	PSA	was	once	recommended	as	a	screening	
test	for	the	disease,	but	the	recommendation	has	been	withdrawn	after	studies	
later	 highlighted	 that	 the	 disease	 can	 be	 present	 even	 when	 serum	
concentrations	 of	 tPSA	 are	 not	 elevated	 (Thompson	 et	 al.,	 2004).	 The	 current	
study	measured	a	variety	of	biomarkers	in	disease‐free	women	during	different	
stages	 of	 reproductive	 activity,	 and	 was	 then	 able	 to	 comment	 upon	 the	
possibility	 that	 the	 biomarkers	 may	 cross	 erroneously	 clinical	 thresholds,	
because	 of	 other	 biological	 processes	 rather	 than	 the	 presence	 of	 the	 disease	
itself.	 Although	 there	 were	 changes	 in	 concentrations	 for	 most	 of	 the	
biomarkers,	it	was	only	CA125	during	early	pregnancy	that	consistently	crossed	
the	 cut‐off	 associated	 with	 disease	 and	 may	 have	 significant	 clinical	
implications.	 The	 clinical	 cut‐off	 for	 CA125	 as	 recommended	 by	 the	 assay	
manufacturer	 is	 35U/ml	 where	 it	 is	 said	 that	 concentrations	 greater	 than	
35U/ml	 are	 associated	 with	 ovarian	 cancer	 and	 other	 gynaecological	 and	
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inflammatory	conditions.	This	study	showed	that	CA125	concentrations	in	early	
pregnancy	peak	between	5	and	6.5	weeks	gestation	(Appendix	11)	and	that	the	
maximum	 concentrations	 often	 exceed	 the	 clinical	 cut‐off	 for	 many	 women	
(Appendix	12).	These	pregnancies	all	resulted	in	a	live	birth	so	it	can	be	inferred	
that	 a	 transient	 elevation	 in	 CA125	 is	 not	 associated	with	 adverse	 pregnancy	
outcomes.		
	
4.5	Summary	
4.5.1		 Findings	
This	study	made	evident	the	importance	of	conducting	a	batch	analysis	of	all	
samples	from	each	of	the	participants	to	make	certain	that	any	changes	seen	
in	 biomarker	 concentrations	 was	 due	 to	 biological	 fluctuation	 and	 not	
because	of	the	increased	batch	to	batch	variation	that	is	associated	with	some	
assays.	 This	 study	 provided	 useful	 information	 about	 the	 precision	 of	 the	
assays	 and	 highlighted	 weaknesses	 in	 some	 such	 as	 CA72‐4	 and	 tPSA,	
particularly	at	low	concentrations.	
	
Ovarian	 stimulation	 appeared	 to	 affect	 serum	 PAPP‐A	 levels	 which	 may	
extent	 into	 pregnancy,	 with	 the	 IVF/ICSI	 cycles	 having	 significantly	 lower	
concentrations,	 whilst	 CA125	 and	 CA15‐3	 were	 unaffected	 by	 ovarian	
stimulation	per	se	but	showed	cyclical	 changes	 throughout	both	 the	natural	
and	 stimulated	 cycles.	 tPSA	 and	 CA72‐4	 showed	 no	 consistent	 changes	 in	
either	natural	or	stimulated	cycles.	PAPP‐A,	CA125,	tPSA	and	CA15‐3	(but	not	
CA72‐4)	 all	 showed	 consistent	 but	 different	 patterns	 of	 change	 in	 early	
pregnancy.		
	
4.5.2		 Implications	
The	biomarkers	studied	provided	additional	information	over	and	above	the	
reproductive	hormones	in	monitoring	the	biological	events	of	ovarian	cycles	
and	 early	 pregnancy.	 In	 pregnancy,	 PAPP‐A,	 CA125,	 PSA	 and	 CA15‐3	 are	
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useful	 in	 combination	 for	 assessing	 different	 aspects	 of	 implantation,	
embryogenesis	 and	 placentation.	 Care	 should	 be	 taken	 when	 interpreting	
CA125	 as	 a	 screen	 for	 gynaecological	 disease	 during	 early	 pregnancy	 as	
transient	elevations	during	this	time	are	normal.	
	
4.5.3		 Limitations	
Although	participant	numbers	were	not	large	(n=35)	the	number	of	serum	
samples	(n=223)	were	adequate	to	provide	statistically	significant	data	at	all	
levels	of	the	study	and	to	reveal	consistent	patterns.	A	limited	number	of	
biomarkers	were	measured,	and	the	additional	value	of	others	cannot	be	
excluded.	All	patients	showed	normal	responses	in	terms	of	ovulation	and	
implantation,	and	the	value	of	these	biomarkers	in	disordered	ovulation	or	
pregnancy	failure	cannot	be	commented	upon.	
     
4.5.4		 Future	Research	
The	 value	 of	 additional	 biomarkers	 that	 can	 be	measured	 using	 automated	
assays	 should	 be	 investigated.	 The	 biomarkers	 of	 the	 current	 study	 should	
also	 be	 applied	 to	 patients	 showing	 disordered	 ovulation	 or	 having	
pregnancies	with	non‐viable	outcomes	such	as	ectopic	implantation,	blighted	
ovum	and	spontaneous	abortion.	
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6.0	Appendices	
Appendix	1	–	Information	letter	and	consent	forms		
 
 RESEARCH PROJECT 
INFORMATION 
 
This research project is being conducted by Melissa Stemp as part of the  
requirements of a Masters Degree (MSc) at Edith Cowan University.  
The title for this student research project is: 
 
Tumour markers: concentrations in the serum of healthy women during 
natural and stimulated ovarian cycles, and during early pregnancy 
 
 
Every healthy person carries low levels of what are known as disease markers.  When diseases occur, 
the level of a particular marker may increase and therefore help with diagnosis (and monitoring) of the 
disease.  But we do not know whether and how hormonal changes in various stages of the reproductive 
cycle may influence the level of these disease markers. 
  
We are inviting you to participate in this study because we are looking for samples 
from perfectly healthy women. 
 
Aim of the project 
a) Measure selected blood tumour markers in women, namely prostate specific antigen (PSA), 
CA15-3, CA72-4, and CA125. 
b) Measure these compounds in healthy women during the natural menstrual cycle, stimulated 
ovarian cycle and early pregnancy. 
c) Determine if the markers fluctuate or are stable, and identify possible changes in these 
compounds that are a normal part of ovulation and pregnancy. 
d) Measure other markers if they become available during the course of the present study, for the 
same reasons. 
 
 
 
 
How can you help? 
Once your blood samples have had hormones measured in the normal way, we would like to use the 
remainder of the samples in the project rather than it being discarded. 
 
How will the sample be used? 
The laboratory at Fertility North will measure levels of the various tumour markers in your blood.  
 
Will these tests tell me if I have cancer? 
No, you have been selected because you are healthy. Results can only be interpreted accurately for 
women at risk of the disease if we understand what happens to these markers in normal women. 
 
Will I get to see the results? 
If you agree for your samples to be used then we shall send you a copy of the final report of the project. 
 
Will the study help me? 
Not directly as the results will not affect your treatment or management. However, it will hopefully 
enable us to understand the dynamics of these tumour markers, which will help others. 
 
Who will see the results of my sample? 
The sample will be coded so that your identity will only be known to the staff at Fertility North.  
 
What if I do not want my sample to be used? 
You are free to refuse for your samples to be used. This will not prejudice your treatment in any way. 
 
Who should I ask if there are any questions? 
Dr Phillip Matson (Scientific Director), Dr Vince Chapple (Medical Director), Melissa Stemp 
(Biochemist) and Dr Angus Stewart (senior Lecturer ECU) are the people involved in the project. These, 
or any of the laboratory staff at Fertility North, will be happy to answer any questions or queries. If you 
require assistance, call Dr Matson on 9301 1075. 
FNC 22. CONSENT FOR THE USE OF BLOOD IN THE RESEARCH PROJECT  
ENTITLED 
Tumour markers: concentrations in the serum of healthy women during natural and stimulated 
ovarian cycles, and during early pregnancy. 
 
Name:  …………………………………………………………….. 
 
Address: …………………………………………………………….. 
 
DOB:  …………………….. 
 
I agree for my blood samples taken in this cycle to be used in this project 
 only for the markers listed in the Research Project Information document,  
 for the markers listed in the Research Project Information document and any other markers as 
additional tumour marker assays become available during the course of this study 
I also understand that: 
a) Refusal would not have prejudiced my treatment in any way. 
b) I am not required to have any extra blood samples taken other than those ordered by my doctor 
for my own management. 
c) I will be sent a copy of the final report of the study so that I may see how the blood samples 
were used, and the conclusions made. 
d) I am free to ask questions of the investigators during the study. 
e) I will be given a copy of this consent form. 
 
 
SIGNATURES 
 
Volunteer: …………………………………………..       date ……………….. 
 
Witness: ……………………………………………..      date ……………….. 
(Must be FN member of staff) 
 
 
The ethical aspects of this study have been approved by the Joondalup Health Campus Human Research Ethics 
Committee and the Edith Cowan University Human Research Ethics Committee.  If you have any complaints or 
reservations about any ethical aspect of your participation in this research, you may contact the Joondalup 
Health Campus Committee through the Executive Office – phone 9400 9404 or Edith Cowan University’s 
Committee through Kim Gifkins – phone 6304 2170.  Any complaint you make will be treated in confidence and 
investigated, and you will be informed of the outcome. 
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Appendix	3	–	Centaur	CP	SOP	
    
 
 
 
 
SOP 
 
Document Number: BC-S-590 
 
 
FA-P-003 
 
 
 
Effective Date: 09-Aug-13 
Operation and Maintenance of the Siemens Centaur CP Analyser 
 
Fertility North documentation is considered PROPRIETARY and is made available for business operations and review by 
Employees of Fertility North and Regulatory Agencies.  Distribution to third parties without written permission is prohibited. 
 
BC-S-590:01                           Effective Date: 09-Aug-13                                                   Page 1 of 6 
 
Purpose: 
To provide Fertility North staff guidance in how to operate the Siemens Centaur CP Automated Analyser in a consistent and 
compliant manner. 
 
Associated Documents: 
BC-F-451 CP Barcode Checklist 
BC-F-459 CP Tube Cap Placemat 
 Advia Centaur CP Manual Operator’s Guide 
 
Definitions: 
FN Fertility North 
 
Responsibilities:  
Role or Department Responsible for: 
Laboratory Technician 
Scientific Director 
 Ensuring that this procedure is adhered to in relation to measuring reproductive 
hormones. 
 Ensuring that this procedure is followed by all staff in the Biochemistry department. 
 Ensuring that all results are validated and reported correctly on the appropriate Fertility 
North documents. 
 
 
 
Table of Contents: 
1 Introduction ............................................................................................................................................................... 2 
2 Reagent Preparation and Storage ........................................................................................................................... 2 
3 Assay Procedure ...................................................................................................................................................... 3 
4 Dilutions of Assays (ADVIA CENAUR CP) .............................................................................................................. 4 
5 Assay Calibration ..................................................................................................................................................... 5 
END OF DOCUMENT ........................................................................................................................................................ 6 
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1 Introduction 
1.1 Assay protocol for estradiol, luteinizing hormone, progesterone, human chorionic gonadotrophin and follicle stimulating 
hormones. 
1.2 Assay – Refer to the Advia Centaur CP - Immunoassay System (See Advia Centaur CP Manual Operator’s Guide). 
 
2 Reagent Preparation and Storage 
2.1 Reagents –For all Siemens Advia Centaur CP supplies a Reagent Diary is kept recording the Order No and date, 
Arrival date, Batch No [same as previous or new], Expiry date, Date opened, and if/when QC reported. All reagents are 
stored as per manufacturer’s instructions. The Order Number and same/new batch are also written on the box. The 
date the box is opened is also recorded on the box. 
2.2 To reconstitute samples, use the pipette pump with a glass volumetric pipette to deliver Reagent Water (filtered in 
Biochemistry through Ibis system) from a sterile specimen container, recording on the sample the date of reconstitution 
and the date of expiry. 
Product Cat No On Board/Recon Stability Storage Temp Volume to Add 
eE2 10491445 672 hrs 2-8 degrees Na 
FSH 1360521 672 hrs 2-8 degrees Na 
LH 2212941 672 hrs 2-8 degrees Na 
PRGE 1586287 672 hrs 2-8 degrees Na 
ThCG 6031151 672 hrs 2-8 degrees Na 
Multi-dil 3 5389133 672 hrs 2-8 degrees Na 
eE2 dil 10491878 672 hrs 2-8 degrees Na 
ThCG dil 5609230 672 hrs 2-8 degrees Na 
Cal 30 10379810 14 days 2-8 degrees 2ml 
Cal B 649625 28 days 2-8 degrees 5ml 
Cal E 4634452 14 days 2-8 degrees 2ml 
Immunoassay Plus 370 na 2-25 degrees 5ml 
Cleaning Soln 9908593 na 2-25 degrees Na 
Wash 1 Soln 1137199 na 2-25 degrees Na 
R1/R2 497043 na 2-25 degrees Na 
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3 Assay Procedure 
3.1 Preparing the Advia Centaur CP for operation 
a) Check on board supplies: - Water, Wash 1, R1/R2, primary/secondary reagents and cuvettes. [These should 
have been replenished at the end of the last run] 
b) Check that waste bin is empty. [This should have been done at the end of the last run] 
c) Perform the Aspirate Probe Bubble Detector Calibration [Maintenance, Aspirate Probe Bubble Detector 
Calibration, and Perform]  
d) Perform the Automated System Prime [Maintenance, Automated System Prime, and Perform] and Close to 
initialise to Ready Mode. 
e) Load Quality Control Ligands, a Patient Repeat from the previous day and any calibrator tubes required. 
Ligands are reconstituted to 5 mls and 7 x 600ul lots are aliquotted and available for the next 7 days. If 
calibrations are due, 500ul from the appropriate reconstituted bottle is put into labelled tubes after ensuring it 
is within its expiry date. 
f) Perform any calibrations due by selecting the reagent tray, selecting reagent due for calibration and selecting 
calibrate. [See3.9 Advia Centaur CP Manual Operator’s Guide] 
g) When this is underway the Ligands and a Patient Repeat from the previous day can have their tests assigned. 
To assign tests, select the sample tray and when the sample is highlighted, add each test. If the sample is 
urgent it can jump the queue by also activating the stat button which shows as orange. If dilutions are 
required, the dilutions button is selected and then the test and the dilution/s. Close the window and if no other 
tests are running you will also need to start CP operation by selecting the start button.  
h) Once calibrations and controls have been run and accepted [see 1.01.21] patient samples can be loaded as 
they become available and tests assigned. 
 
3.2 Preparation and completion of a Daily Worksheet   
a) Open PowerTerm, and select D- Biochemistry menu. 
b) Select A-New Worksheet, and ESC to accept the worksheet number and date. 
c) Select F2, enter the date of birth, and select the matching patient. 
d) Assign the sample number using the barcode reader unless it is unavailable in which case the number can be 
entered manually. 
e) Select F3 and using arrows to find test Select F4 to assign. Unless samples are going into patient history 
rather than a cycle [assigned by nurses] the daily reference must accompany the sample. [F5 is used for this]. 
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f) Once the samples are entered, hit F1 to go back to the menu. The Biochemistry worksheet is saved.  
g) Results are manually entered from the Advia Centaur CP output - Results, Print, Today’s Records, 
Consolidated Results and OK. 
h) Results are transferred into PowerTerm by selecting C-Worksheet Double Entry from the Biochemistry menu 
and entering each result twice. 
i) Once complete, the worksheet is printed by choosing D-Worksheet Result List and cross-checked against the 
Advia Centaur CP. 
j) When Biochemistry staff have completed and checked results, they must validate the worksheet, making it 
available for viewing and comment by Clinicians and nursing staff. To validate the worksheet choose A-
Biochemistry Worksheet, ensuring the correct sheet is chosen by number (there may be more than one) then 
choose F2 to validate and Y to confirm.   
k) Sign validation form and file with complete set of day’s paperwork including all result printouts from the CP 
and completed worksheets from Powerterm. 
 
4 Dilutions of Assays (ADVIA CENAUR CP) 
4.1 Estradiol 
Samples >11000 pmol/L will be automatically diluted by the Advia Centaur CP.  If high or unpredictable levels are 
expected samples can be pre programmed for selected dilutions when assigning the test. (See 2.42 Advia Centaur CP 
Operator's Guide). 
 
4.2 Progesterone 
Samples >150 nmol/L will be automatically diluted by the Advia Centaur CP.  Some luteal phase and pregnant patients 
may have higher levels and if high or unpredictable levels are expected samples can be pre programmed for selected 
dilutions when assigning the test. (See 2.42 Advia Centaur CP Operator's Guide) 
 
As a guide, levels remain fairly constant throughout early pregnancy but vary between patients. Assume level will be 
similar to the last sample. If borderline, leave to run neat as the test is a short one and the repeat does not result in 
excessive delays. 
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4.3 LH (Luteinizing Hormone) 
Samples greater than 150 IU/L do not need to be diluted and should just be quoted as such. 
 
4.4 FSH (Follicle Stimulating Hormone) 
Samples greater than 110 IU/L do not need to be diluted and should just be quoted as such.  
 
4.5 ThCG (Total Human Chorionic Gonadotrophin) 
Samples >1000 IU/L will be automatically diluted by the Advia Centaur CP.  Only samples of patients who are pregnant 
will have continually escalating levels and will need to be diluted. Samples can be pre programmed for selected 
dilutions when assigning the test. (See 2.42 Advia Centaur CP Operator's Guide) 
 
As a guide, if the previous result was <500, then run neat; if >500 then run at 1/100; and if   >50000 then run at 1/200. 
 
5 Assay Calibration  
5.1 For estradiol, luteinizing hormone, progesterone, human chorionic gonadotrophin and follicle stimulating hormones.  
5.2 Frequency of calibration [see 3.9 Advia Centaur CP Operator’s Guide) 
a) LH, Progesterone and ThCG – Monthly 
b) Estradiol and FSH  – 14 days 
c) When new reagent and calibration lots are introduced. 
d) Upon poor QC performance 
 
5.3 Application of Calibrators 
a) LH, FSH, ThCG – Cal B 
b) Progesterone – Cal E 
c) Estradiol – Cal 30 
 
The bottles specify the amount of water to add. When this is done the reconstitution and expiry dates are written on the 
bottle. 
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5.4 Calibration of Assays (see3.11-17 Advia Centaur CP Operator’s Guide) 
a) Prior to calibration check assay and calibration lot numbers:  Scan new assay master curve barcodes if 
required. Try and ensure that the calibrator has been reconstituted at least a day prior to use and at the other 
extreme, that it is not expired. 
b) Prior to daily assay runs, perform any calibrations due by selecting reagent tray, selecting reagent due for 
calibration and selecting calibrate. 
 
END OF DOCUMENT 
 
 
 
  
80 
 
 
Appendix	4	–	Roche	SOP	
 
SOP
Document Number: BC-S-542 Effective Date: 09-Aug-13
Operation and Maintenance of the Roche COBAS e411 Analyser
Fertility North documentation is considered PROPRIETARY and is made available for business operations and review by
Employees of Fertility North and Regulatory Agencies.  Distribution to third parties without written permission is prohibited.
BC-S-542:01                                   Effective Date: 09-Aug-13                                                   Page 1 of 8
Purpose:
To provide Fertility North staff guidance in how to operate the Roche Cobas e411 Automated Analyser in a consistent and
compliant manner.
Associated Documents:
BC-F-410 Screening Tests Schedule
BC-F-411 Screening Results Worksheet
Roche Cobas e411 analyser operators manual
Definitions:
FN Fertility North
Responsibilities:
Role or Department Responsible for:
Laboratory Technician
Scientific Director
? Ensuring that this procedure is adhered to in relation to screening bloods.
? Ensuring that this procedure is followed by all staff in the Biochemistry department.
? Ensuring that all results are validated and reported correctly on the appropriate Fertility
North documents.
Table of Contents:
1 Start-up / Pre-routine Operation Procedures ............................................................................................................... 2
1.1.6    Open lids and check for surface bubbles. If present, aspirate gently with a plastic pipette. .......................... 2
2 Routine Operation ............................................................................................................................................................. 4
END OF DOCUMENT ................................................................................................................................................................. 8
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1 Start-up / Pre-routine Operation Procedures
1.1 Preparing the Roche Cobas e411 for Operation
1.1.1 Perform a visible inspection of the machine, noting all surfaces are clean and free from debris, probes and
microbead mixer paddle are in good condition and not bent, no tubing is pinched or bent, and pipette syringes
and associated tubing are free of bubbles and not leaking system water. If these fail inspection, then remedy by
cleaning or calling the Roche Support Service.
1.1.2 Ensure that printer is switched on and contains paper.
1.1.3 With the analyser in Standby mode, top up system water with a 100+1 solution of SysWash in deionised water
(10ml: 1L).
1.1.4 Empty liquid waste container and rinse with water, and empty solid waste tray. Ensure safety glasses and gloves
are worn when emptying biohazard material.
1.1.5 Allow reagent packs to warm to room temperature and then load on to the reagent rotor the reagent packs for the
tests to be run that day. The rotor is temperature controlled to 20°C.
  1.1.6 Open lids and check for surface bubbles. If present, aspirate gently with a plastic pipette.
1.1.7 Check the reagents (ProCell and CleanCell bottle sets) and consumables (AssayCup and AssayTip trays), and
ensure sufficient are on board. Top up as required, ensuring that new lots of reagents are calibrated, and the
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ProCell and CleanCell are added in pairs. The chambers holding the ProCell and CleanCell are kept to a
temperature of 28.0°C, and so reagents must be allowed 15 minutes to achieve this working temperature.
1.1.8 Open the ProCell and CleanCell lids.
1.1.9 From the home screen select the button to run a Reagent Scan. The reagent scan will check how many
AssayTips and AssayCups are onboard as well as the ProCell and CleanCell levels. It also scans the barcodes
on any reagent packs that are on board the analyser. The analyser will register any new lots and determine if the
new kits requires a calibration before it will allow it to be run.
1.1.10 The analyser is now ready for use.
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2 Routine Operation
1.1 Instrument Calibration / Quality Control
2.1.1 Calibrations should be performed at the frequency summarised in Table 2.1 and indicated below for the individual
assays. Expired calibrators should not be used and should be discarded.
2.1.2 Calibrator details are entered using the calibrator barcode card which is inserted in the barcode reader to the left
of the reagent rotor.
2.1.3 If using Position Assignment to indicate the Calibrators, then ensure that the barcode on the tube is not visible to
the scanner and that the lot number of the Calibrator is assigned to the correct positions. This is done at
Workplace>Calibration>Calibrator>Position Assignment. Select the Calibrator lot on the left of the screen, and the
rack position on the right of the screen, and choose Assign. If a previous Lot is in the rack positions then these
will need to be removed first.
2.1.4 Check if a Calibration or QC is requested by the system (Overview Screen > Calib/QC Load List)
2.1.5 Check if calibration renewal is due on each of the reagent packs. If manual calibrations are required select these
from the Calibration menu > Status > Highlight test > Select Full > Save.
2.1.6 Running the Calibrations is simply a case of placing the Calibrators in the correct rack position in the front tray
and pressing Start. Ensure that the Calibration was successful before running QCs and samples.
2.1.7 Request non-Roche controls from the QC menu > Status Highlight Control > Select > Save.
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2.1.8 Prepare calibrator and control materials i.e. reconstitute lyophilized material or thaw frozen material. Always refer
to the specific calibrator or control package insert for details.
2.1.9 Load required controls using the designated Control racks. When loading controls, ensure both levels of the same
control are next to each other on the rack with level 1 in the position in front of level 2.
2.1.10 Start measuring controls (Start > Start).
2.1.11 Once sampling is complete, remove calibrators and controls from the racks, promptly close the lids and return
them to the refrigerator.
2.1.12 Validate Calibration and Control results. Write into Endocrinology or Serology workbook and file the printed copy
under Roche Daily QC & Calibration Printouts.
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1.2 Sample Processing
2.2.1 Remove samples from the fridge and allow them to warm to room temperature.
2.2.2 Using sample racks held on a metal tray, samples are added to each rack with their barcode visible through the
rack opening, as listed in the tests schedule (BC-F-410) which defines which position each patient sample is in.
2.2.3 Once all the racks are loaded on the tray, the tray is placed in to the front compartment (A-line) of the analyser,
ensuring there is a tray on the back area, C-line, to receive the racks.
2.2.4 Press Start so that the samples pass through bar code reader.
2.2.5 Choose Workplace>Data Review and select the first tube that was read.
2.2.6 Program the patient samples by pressing Workplace > Test Selection.
2.2.7 Select the Routine option from the Sample area on the top left of the screen. A sequence number is assigned
automatically.
2.2.8 Select the Normal or Reduced option for Sample Cup.
2.2.9 Select the required dilution, if any.
2.2.10 Select the tests for the sample on the test key matrix. Once selected the test appears white.
2.2.11 Choose Save to complete the test selection.
2.2.12 Once done, bring the tray forward from the C-line back to the A-line, and replace a tray in the C-line.
2.2.13 Press Start > Start to run the samples for sampling and analysis.
2.2.14 Track sample processing by selecting Sample Tracking from the Overview screen.
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1.3 Result Evaluation
2.3.1 Print patients result reports by choosing Workplace > Data Review. Highlight all patient samples and press Print >
Print.
2.3.2 Transcribe individual patient results onto the Screening Results Worksheet document (BC-F-411). This sheet will
have the matching patient barcode that is on the sample tube and the Screening Test Schedule (BC-F-410) at the
header of the patient’s results column.
2.3.3 The assay scientist validates the results written onto the Screening Results Worksheet from the hard copy that
has been printed off the Roche Cobas e411 Analyser.
2.3.4 A secondary scientist that did not run the assays then co-validates the results written onto the Screening Results
Worksheet from the original hard copy that was printed off the Roche Cobas e411 Analyser.
2.3.5 After the results have been validated by both scientists, the results are transcribed into the appropriate word
documents; “Serology Female Master” or “Serology Male Master” or “Endocrinology Female Master” or
“Endocrinology Male Master”.
2.3.6  A copy of each individual patients report is saved as Surname, Initial and the date of processing.
2.3.7 The report is copied and pasted into a new template in the patients file on Genie. The appropriate template can
be found under the Lab Reports heading. Once the template is complete and all patient details are checked and
correct the document is saved to the patients file.
2.3.8 A copy of the report is printed from the patients overview screen and is paired with the original results print out
from the Roche Cobas e411 Analyser and the Screening Results Worksheet. These are sent to the Scientific
Director for final validation.
1.4 Result Final Validation
2.4.1 The Scientific Director, or his nominated deputy,  is to give the final validation of all screening results by viewing
the patient’s final report generated through the Genie program and validating that the result is the same as what
was originally printed off the Roche Cobas e411 Analyser.
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1.5 End of Operation / Daily Maintenance
2.5.1 Once the analyser has gone back into Standby mode you are then able to open the reagent rotor lid and press
down on the reagent caps to snap them shut. Remove all reagent packs and store in the refrigerator. Replace
rotor lid and lock.
2.5.2 Replace AssayTip and AssayCup trays that are empty.
2.5.3 Empty solid waste container and liquid waste containers ensuring safety glasses and gloves are worn to avoid
contact with hazardous material.
2.5.4 Clean the sample/reagent probe with alcohol swabs daily and check for condensation inside compartments.
2.5.5 Close the ProCell and CleanCell lids to prevent evaporation.
2.5.6 Perform any other scheduled maintenance e.g. weekly or monthly maintenance.
o Weekly. Clean the sipper probe to prevent contamination and carryover. In addition, spills on the
incubator may cause gripper movement alarms, and so the incubator and aspiration station should be
cleaned. Empty the system water container irrespective of the amount contained and rinse with water,
then refill with 1+100 diluted SysWash.
o Fortnightly. Clean the rinse stations for the sample/reagent probe and microbead mixer, plus the one
for the sipper probe. Liquid flow cleaning should be performed in the correct sequence to keep the
sipper liquid flow clean and maintain the integrity of the measuring cell.
o Bimonthly. Replace the pinch valve tubing every two months.
o As needed. Clean the liquid waste container and the microbead mixer. Also, clean the ProCell and
CleanCell compartments. Clean the reagent rotor and compartment.
o Ensure the Cobas e411 analyser maintenance log is completed.
END OF DOCUMENT
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Appendix	5	–	Siemens	Reagent	Stabilities 
Na = not applicable as product is supplied in liquid form. 
 
 
 
 
Product	 Cat	No	 On	Board/Recon	
Stability	 Storage	Temp	
Volume	
to	Add	
eE2	 10491445	 672	hrs	 2‐8	degrees	 Na	
FSH	 1360521	 672	hrs	 2‐8	degrees	 Na	
LH	 2212941	 672	hrs	 2‐8	degrees	 Na	
PRGE	 1586287	 672	hrs	 2‐8	degrees	 Na	
ThCG	 6031151	 672	hrs	 2‐8	degrees	 Na	
Multi‐dil	3	 5389133	 672	hrs	 2‐8	degrees	 Na	
eE2	dil	 10491878	 672	hrs	 2‐8	degrees	 Na	
ThCG	dil	 5609230	 672	hrs	 2‐8	degrees	 Na	
Cal	30	 10379810	 14	days	 2‐8	degrees	 2ml	
Cal	B	 649625	 28	days	 2‐8	degrees	 5ml	
Cal	E	 4634452	 14	days	 2‐8	degrees	 2ml	
Immunoassay	
Plus	 370	 ‐	 2‐25	degrees	 5ml	
Cleaning	Soln	 9908593	 ‐	 2‐25	degrees	 Na	
Wash	1	Soln	 1137199	 ‐	 2‐25	degrees	 Na	
R1/R2	 497043	 ‐	 2‐25	degrees	 Na	
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Appendix	6	–	Roche	Reagent	Stabilities 
	
Assay	
	
Test	
time	
Stability	 Calibration	
	
Measuring	range	
Unopened	
2‐8°C	
Opened	
2‐8°C	
On‐board	
analyser	 Initial	
On‐board	
analyser	
Stored	same	
lot	
CA125	II	 18	mins	 Exp.	Date	 12	weeks	 6	weeks	 Within	24hrs	 7	days	 1	month	 0.6‐5,000	U/mL	
CA15‐3	II	 18	mins	 Exp.	Date	 12	weeks	 5	weeks	 Within	24hrs	 7	days	 1	month	 1.00‐300	U/mL	
CA72‐4	 18	mins	 Exp.	Date	 12	weeks	 8	weeks	 Within	24	hrs	 7	days	 1	month	 0.200‐300	U/mL	
tPSA	 18	mins	 Exp.	Date	 12	weeks	 4	weeks	 Within	24hrs	 7	days	 1	month	 0.003‐100	ng/mL	
PAPP‐A	 18	mins	 Exp.	Date	 4	weeks	 3	weeks	 Within	24	hrs	 7	days	 1	month	 4‐10000	mIU/L	
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Appendix	7	–	Roche	QC	Material 
	
 
Assay	 QC	material	 No.	
Levels
Reconstitution	 Storage	 Stability
CA125,	
CA15‐3,	
CA72‐4,	
tPSA	
Elecsys	
PreciControl	
Tumor	marker	
2	 3	mls	water	each	 ‐20˚C	 1	month	
CA125,	
CA15‐3,	
CA72‐4,	
tPSA	
Biorad	Lyphochek	
Tumor	Marker	Plus 3	
2	mls	water	
each	 ‐20˚C	 1	month	
PAPP‐A	
Elecsys	
PreciControl	
Maternal	Care	
3	 3	mls	water	each	 ‐20	˚C	
3	
months	
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	Appendix	8	–	Change	in	mean	concentration	of	CA125	in	ovarian	
cycles,	natural	and	stimulated	combined.	
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Appendix	9–	Change	in	the	mean	concentration	during	early	pregnancy	
of	CA125,	CA15‐3	and	tPSA.	
 
 
	
